Human antibodies that bind RET and methods of use thereof
Patent Information
- Application Number
- MX2021012335
- Authority / Receiving Office
- MX · MX
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-10
- Filing Date
- 2021-10-07
- Publication Date
- 2026-10-05
- Estimated Expiration
- 2040-04-09
AI Technical Summary
Current therapies for RET-expressing tumors lack specificity and efficacy, leading to adverse effects, and there is a need for potent human antibodies that can inhibit RET signaling without such side effects.
Development of fully human monoclonal antibodies and antigen-binding fragments that specifically bind to RET, inhibiting the interaction with GDNF family ligands and their co-receptors, thereby modulating RET signaling.
These antibodies effectively inhibit RET signaling, offering a potential therapeutic approach for various cancers and conditions associated with RET expression, including thyroid, lung, pancreatic, breast, and skin cancers, while minimizing adverse effects.
Abstract
Description
HUMAN ANTIBODIES THAT BIND TO RET AND METHODS OF THEIR USE Field of invention The present invention relates to human antibodies and human antibody antigen-binding fragments that bind specifically to the RET tyrosine kinase receptor (rearranged during transfection), compositions comprising these antibodies, and therapeutic methods for using these antibodies. Information about the sequence list An official copy of the sequence list is provided electronically with the specification via EFS-Web as an ASCII-formatted sequence list with the filename 10582W001_SeqList_ST25.TXT, a creation date of April 9, 2020, and a size of approximately 168 kilobytes. The ASCII-formatted sequence list in this document forms part of the specification and is incorporated by reference in its entirety. Statement of the related technique The receptor tyrosine kinase REarranged during transfection (RET) is expressed during development in a variety of tissues, including the central and peripheral nervous systems and the kidney (Arighi, E. et al, (2005), Cytokine Growth Factor Rev 16:441-467; Borrello, MG, et al, (2013), Expert Opin. Ther. Targets, 17(4):403-419; Golden, JP, et al. (1998), J. Comp. Neurol. 398:139-150; Golden, JP, et al. (1999), Exp. Neurol. 158:504-528). It is also expressed in neural crest-derived cells and regulates cell proliferation, migration, and survival (Coulpier, M. et al, (2002), J Biol Chem, 277:1991-1999; Golden, JP, et al. (1998), J. Comp. Neurol. 398:139-150; Golden, JP, et al. (1999), Exp. Neurol. 158:504-528). RET knockout mice exhibit renal agenesis and lack enteric neurons in the digestive tract.A very similar phenotype is observed in both GFRα and GDNF knockout mice, confirming a major role for GDNF / GFRa1 in the activation of RET signaling during development. RET is the signaling receptor for ligands of the glial cell-derived neurotrophic factor (GDNF) family, which includes GDNF, artemin, neurturin, and persephin. GDNF family ligands interact with and activate RET only in the presence of one of four GPI-linked coreceptors, known as GDNF family GFRD receptors (1-4) (Baloh, RH, et al. (2000), Curr Opin Neurobiol 10:103-110; Borrello, MG, et al. (2013), Expert Opin. Ther. Targets, 17(4):403-419). The primary ligands for the coreceptors GFRal, GFRa2, GFRa3 and GFRa4 are GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN), respectively, although an interaction between ligands and coreceptors has been observed in vitro. The role of RET as a driver of tumorigenesis has been established by the activating mutations that are frequently observed in the multiple endocrine neoplasia syndromes MEN2A and MEN2B and in familial medullary thyroid cancer (Mulligan, LM, et al, (1994), Nat. Genet. 6:70-74). crczLn / Lznz / E / Yii Furthermore, a large percentage of sporadic medullary thyroid cancers contain activating somatic mutations in RET (Fusco, A. et al, (1987), Nature 328:170-172; Grieco, M. et al, (1990), Cell 60:557-563). These mutations can occur in the kinase domain or in the extracellular domain, where they result in unpaired cysteines that are thought to promote ligand-independent dimerization and activation of RET. Thus, the tumorigenic potential of RET in humans has been clearly established through genetic studies. In addition to its role in endocrine cancers, recent work has identified RET as a potential therapeutic target in breast cancer. RET and GFRα are expressed in breast cancer cell lines and in primary human breast cancer samples. Interestingly, RET and GFRα expression can be induced by estrogen in vitro. Consistent with this observation, RET and GFRα are preferentially expressed in the estrogen receptor-positive subset of breast cancers. Furthermore, GDNF-induced RET signaling promotes growth independent of estrogen receptor-positive breast cancer cells' attachment to the estrogen receptor and potentiates the effects of estrogen on the growth and survival of these cells, indicating functional cooperation between these two pathways. Therefore, RET signaling appears to be an important driver of the oncogenic phenotype in breast cancer cells (Wang, C.).et al. (2012), Breast Cancer Res Treat 133(2):487-500; Stine, ZE, et al. (2011), Human Molecular Genetics 20(19):3746-3756). RET activation is initiated by the binding of GDNF to GFRα. The GDNF / GFα1 complex then binds to RET, resulting in dimerization and activation of the receptor. Several small molecules have the ability to inhibit RET, including vandetanib, which has shown activity in patients with medullary thyroid cancer (see Wells, SA et al, (2012), J Clin Oncol 30:134-141; Leboulleux, S. et al, (2012), Lancet Oncol 13:897-905). Other small molecules that bind to and inhibit RET signaling have been identified (Borrello, MG, et al, (2013), Expert Opin. Ther. Targets, 17(4):403-419). Unfortunately, due to their lack of specificity, some of these compounds have experienced adverse events in clinical trials, hindering further development. To date, there have been no reports of therapeutic anti-RET monoclonal antibodies for use in a clinical setting to treat RET-expressing tumors. The studies reported herein describe the generation of fully human monoclonal antibodies that bind to RET and prevent RET from interacting with one or more members of the GDNF family complexed with their corresponding coreceptors. The structure of the RET extracellular domain is shown in Figure 1 and consists of four cadherin-like domains followed by a cisterna-rich domain (see Borrello, MG, et al (2013), Expert Opin. Ther. Targets, 17(4):403-419). While the structure of the active RET signaling complex has not been resolved, it appears that the GDNF / GFRa1 complex contacts the RET extracellular domain at multiple sites, including the fourth cadherin-like domain and the cisterna-rich domain. Therefore, antibodies directed against multiple RET domains could potentially inhibit signaling. Antibodies against RET have been described and can be found in patents US6861509 and US2009 / 0136502. crczLn / Lznz / E / Yii However, given the role RET plays in the growth and proliferation of tumor cells, and given that there are few approved agents targeting this molecule, there is still a need for RET inhibitors, for example, human antibodies that bind specifically to RET, that are very potent and do not produce adverse effects that would preclude approval for clinical use. Brief description of the invention The invention provides fully human monoclonal antibodies (mAbs) or antigen-binding fragments thereof that specifically bind to RET and inhibit the binding or interaction of RET with one or more ligands belonging to the GDNF family (GDNF, neurturin, artemin, and persephin) complexed with their corresponding coreceptors (GFR1, GFR2, GFR3, and GFR4, respectively). In one embodiment, the human anti-RET antibodies described herein prevent the interaction of RET with the GDNF / GFRa1 complex. In a related embodiment, the human anti-RET antibodies described herein prevent the interaction of RET with the artemin / GFRa3 complex. In a related embodiment, the human anti-RET antibodies described herein prevent the interaction of RET with the neurturin / GFRa2 complex or the persephin / GFRa4 complex. The studies described herein have demonstrated that these antibodies are capable of modulating ligand-dependent RET signaling. In certain modalities, antibodies that antagonize ligand-dependent RET signaling have been identified. Given the role RET plays in the development of multiple endocrine neoplastic syndromes, as well as other cancers, the antibodies of the invention that antagonize / inhibit RET signaling activity can be used in the treatment of these neoplastic syndromes and cancers to inhibit tumor cell growth / proliferation. Examples of cancerous conditions that can be treated using the RET antagonist antibodies of the invention include, but are not limited to, thyroid tumors, lung tumors, pancreatic tumors, skin cancers, breast cancer, and leukemias. A thyroid tumor that can be treated using an anti-RET antagonist antibody of the invention may include papillary thyroid carcinoma (PTC) or medullary thyroid carcinoma (MTC).Medullary thyroid carcinoma treatable using an antagonistic anti-RET antibody of the invention may include hereditary MTCs selected from the group consisting of MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC) syndrome, or the medullary thyroid carcinoma may be a sporadic MTC. The antibodies of the invention may also be used to treat pain associated with these cancerous conditions, as well as pain associated with other diseases, disorders, or conditions in which RET activity or signaling may play a role. Antibodies can be used as standalone therapy or in combination with a second agent to treat a disease or disorder associated with RET expression. In certain modalities, antibodies can be administered therapeutically along with a second agent to treat the disease or disorder, or to improve at least one symptom associated with it. If the antibody inhibits RET activity or signaling and is being considered for treatment of, for example, a cancerous condition, the second agent may be a chemotherapeutic agent, a bone marrow regenerator, or radiation therapy to treat the tumor.If the antibody inhibits RET activity or signaling and is being considered for treating pain associated with a particular condition, and if the treatment warrants the use of a second pain-reducing agent, the second agent may be any agent that is also useful in relieving pain associated with that condition, such as aspirin or another NSAID, morphine, steroids (e.g., prednisone), a nerve growth factor (NGF) inhibitor (e.g., a small-molecule NGF antagonist or an anti-NGF antibody), an anti-Nav1.7 antibody or a small-molecule anti-Nav1.7 inhibitor, a Nav1.8 antagonist (e.g., an anti-Nav1.8 antibody or a small-molecule Nav1.8 inhibitor), or a Nav1.9 antagonist (e.g., an anti-Nav1.9 antibody or a small-molecule Nav1 inhibitor).9), a cytokine inhibitor (for example, an interleukin-1 (IL-1) inhibitor (such as rilonacept (IL-1 trap) or anakinra (KINERET®), a small molecule IL-1 antagonist or an anti-IL-1 antibody; an IL-18 inhibitor (such as a small molecule IL-18 antagonist or an anti-IL-18 antibody); an IL-6 or IL-6R inhibitor (such as a small molecule IL-6 antagonist, an anti-IL-6 antibody or an IL-6 receptor antibody), caspase-1, p38, IKK1 / 2, CTLA-4γ inhibitors, or an opioid. The antibodies of the invention may be full length (e.g., an IgG1 or lgG4 antibody) or may comprise only an antigen-binding portion (e.g., a Fab fragment, F(ab')2 or scFv), and may be modified to affect functionality, e.g., to eliminate residual effector functions (Reddy et al., (2000), J. Immunol. 164:1925-1933). Accordingly, in a first aspect, the invention provides an isolated human monoclonal antibody or an antigen-binding fragment thereof that binds specifically to the RET (REarranged during Transfection) tyrosine kinase receptor, wherein the antibody has one or more of the following characteristics: (A) is a fully human antibody; (b) exhibits a Kd that ranges from approximately 1.0 X 107M to approximately 1.0 X 10-12M as measured by surface plasmon resonance; (c) inhibits or blocks the binding or interaction of RET with one or more ligands belonging to the GDNF family (GDNF, neurturin, artemin and persephin) complexed with their corresponding coreceptors (GFR1, GFRRa2, GFRRa3 and GFRRa4, respectively); (d) inhibits RET signaling mediated by one or more GDNF family ligands selected from GDNF, neurturin, artemin, and persephin; (e) enhances internalization / degradation by RET after antibody binding to RET receptor; (f) comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290; or (g) comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. crczLn / Lznz / E / Yii In one modality, the isolated human monoclonal antibody or the antigen-binding fragment thereof that specifically binds to RET blocks the binding of human RET to the GDNF:GFRa1 co-complex with an ICso value ranging from approximately 100 pM to approximately 7.0 nM. In a related modality, the isolated human monoclonal antibody or the antigen-binding fragment thereof that specifically binds to RET blocks the binding of human RET to the GDNF:GFRa1 co-complex with an ICso value ranging from approximately 250 pM to approximately 5.2 nM. In one modality, the isolated human monoclonal antibody or the antigen-binding fragment thereof that specifically binds to RET blocks the binding of human RET to the GDNF:GFRa1 co-complex by approximately 40% to approximately 100%. In a related modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET blocks the binding of human RET to the GDNF:GFRa1 co-complex by approximately 57% to approximately 97%. In one modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET inhibits GDNF-mediated RET signaling with an ICso value ranging from approximately 50 pM to over 100 nM. In a related modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET inhibits GDNF-mediated RET signaling with an ICso value ranging from approximately 143 pM to over 100 nM. In one modality, the isolated human monoclonal antibody or antigen-binding fragment that specifically binds to RET inhibits GDNF-mediated RET signaling by approximately 40% to approximately 100%. In a related modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to RET inhibits GDNF-mediated RET signaling by approximately 60% to approximately 100%. In one modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to RET inhibits artemin-mediated RET signaling with an ICso value ranging from approximately 100 pM to approximately 500 nM. In a related modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET inhibits artemin-mediated RET signaling with an ICso value ranging from approximately 250 pM to approximately 341 nM. In one modality, the isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to RET inhibits artemin-mediated RET signaling by approximately 57% to approximately 100%. In one embodiment, the isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to RET, comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290. In one embodiment, the human isolated monoclonal antibody or antigen-binding fragment of crczLn / Lznz / E / Yii itself that specifically binds to RET, comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. In one embodiment, the isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to RET, comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290; and a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. In one embodiment, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET comprises a pair of HCVR / LCVR amino acid sequences selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, and 290 / 298. In one embodiment, the isolated human monoclonal antibody or antigen-binding fragment that specifically binds to RET comprises an HCVR comprising the three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within an HCVR amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, and 290; and an LCVR comprising the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within an LCVR amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. The methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the field and can be used to identify CDRs within the specified HCVR and / or LCVR amino acid sequences described herein. Exemplary conventions that can be used to identify CDR boundaries include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Generally speaking, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a consensus between the Kabat and Chothia approaches. See, for example, Kabat, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD (1991); Al-Lazikan et al., (1997), J. Mol. Biol. 273:927-948; and Martin et al., (1989), Proc. Nati. Academic Sel. USA 86^268-9272.Public databases are also available to identify CDR sequences within an antibody. In one embodiment, the isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to RET comprises: (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276 and 292; crczLn / Lznz / E / Yii (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278 and 294; (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280 and 296; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284 and 300; (e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286 and 302; and (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288 and 304. In one embodiment, the invention provides an isolated antibody or antigen-binding fragment thereof that binds specifically to RET, which competes for specific binding to RET with an antibody or antigen-binding fragment comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282 and 290 / 298. In one embodiment, the invention provides an isolated antibody or antigen-binding fragment thereof that binds specifically to RET, which binds to the same epitope on RET that is recognized by an antibody comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282 and 290 / 298. In one embodiment, the invention provides a fully human monoclonal antibody or an antigen-binding fragment thereof that binds specifically to RET, wherein the antibody or fragment thereof exhibits one or more of the following features: (i) comprising an HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (i) comprises an LCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity;(i¡¡) comprises an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280 and 296, or a substantially crczLn / Lznz / E / Yii similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288 and 304, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity;(iv) comprises an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276 and 292, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (v) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278 and 294, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity;(vi) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284 and 300, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (vii) and an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286 and 302, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (viii) exhibits a Kd ranging from approximately 1 X 107M to approximately 1 X 1012M; (ix) is capable of blocking the binding of human RET to the GDNF:GFRa1 co-complex with an ICso value of less than approximately 5.2 nM;or (x) demonstrates the ability to inhibit ligand-dependent RET signaling by approximately 60 to 100% with an ICso value ranging from approximately 143 pM to over 100 nM.; In a second aspect, the invention provides nucleic acid molecules encoding antibodies or fragments thereof that bind specifically to RET. The recombinant expression vectors carrying the nucleic acids of the invention and the host cells into which these vectors have been introduced are also included in the invention, as are the methods for producing the antibodies by culturing the host cells under conditions that permit antibody production, and recovering the antibodies produced. In one embodiment, the invention provides an antibody or fragment thereof comprising an HCVR encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1,17, 33, 49, 65, 81,97,113,129,145, 161,177,193,209, 225, 241,257, 273 and 289 or a substantially identical sequence having at least 90%, at least 95%, at least 98%, or at least 99% homology thereof. In one embodiment, the antibody or fragment thereof further comprises an LCVR encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 9, 25, 41, 57, 73, 89, 105, 121, 137, 153, 169, 185, 201, 217, 233, 249, 265, 281 and 297, or a substantially identical crczLn / Lznz / E / Yii sequence having at least 90%, at least 95%, at least 98% or at least 99% homology thereof. In one embodiment, the invention also provides an antibody or antigen-binding fragment of an antibody comprising an HCDR3 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 7, 23, 39, 55, 71, 87, 103, 119, 135, 151, 167, 183, 199, 215, 231, 247, 263, 279 and 295, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and an LCDR3 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 15,31, 47, 63, 79, 95, 111, 127, 143, 159, 175, 191,207, 223, 239, 255, 271,287 and 303, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. In one embodiment, the invention provides an antibody or fragment thereof further comprising an HCDR1 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, 19, 35, 51, 67, 83, 99, 115, 131, 147, 163, 179, 195, 211, 227, 243, 259, 275 and 291, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; an HCDR2 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 5, 21, 37, 53, 69, 85, 101, 117, 133, 149, 165, 181, 197, 213, 229, 245, 261, 277 and 293, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity;an LCDR1 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, 27, 43, 59, 75, 91, 107, 123, 139, 155, 171, 187, 203, 219, 235, 251, 267, 283 and 299, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and an LCDR2 domain encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 13, 29, 45, 61, 77, 93, 109, 125, 141, 157, 173, 189, 205, 221, 237, 253, 269, 285 and 301, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. In a third aspect, the invention presents a human antibody or antigen-binding fragment specific for RET comprising an HCVR encoded by nucleotide sequence segments derived from germline sequences Vh, Dh and Jh, and an LCVR encoded by nucleotide sequence segments derived from germline sequences Vk and Jk. The invention encompasses antibodies having a modified glycosylation pattern. In some applications, modification to remove undesirable glycosylation sites may be useful, or, for example, the removal of a fucose portion to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In other applications, modification of galactosylation can be performed to modify complement-dependent cytotoxicity (CDC). In a fourth aspect, the invention provides a pharmaceutical composition comprising at least one isolated fully human monoclonal antibody or antigen-binding fragment of the crczLn / Lznz / E / Yii antibody that binds to RET, and a pharmaceutically acceptable vehicle or diluent. In one embodiment, the invention provides a pharmaceutical composition comprising two fully human monoclonal antibodies or antigen-binding fragments thereof, which bind to the same epitope or to two different epitopes on RET, and a pharmaceutically acceptable vehicle or diluent. It is understood that any combination of antibodies as described herein may be used in a pharmaceutical composition to achieve the desired results in the patient population requiring such therapy. For example, two antibodies that recognize and / or bind to RET may be used in a composition. In one embodiment, the composition comprises an antibody that binds to RET and has a pair of HCVR / LCVR amino acid sequences selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282, and 290 / 298. In one embodiment, the pharmaceutical composition comprises at least one RET-binding antibody, wherein the antibody comprises the three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3) contained within any of the heavy chain variable region (HCVR) amino acid sequences selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, and 290; and the three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any of the light chain variable region (LCVR) amino acid sequences selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. In one embodiment, the antibodies of the invention or compositions containing one or more antibodies of the invention can be used to inhibit at least one activity or function associated with RET expressed in a cell. In one embodiment, the cell can be a tumor cell. In one embodiment, the activity can be cell signaling. In one embodiment, the invention features a composition, which is a combination of an antibody or antigen-binding fragment of an antibody of the invention and a second therapeutic agent. The second therapeutic agent may be a small molecule drug, a protein / polypeptide, an antibody, or a nucleic acid molecule, such as an antisense molecule or siRNA. The second therapeutic agent may be synthetic or naturally derived. The second therapeutic agent may be any agent that combines advantageously with the antibody or antibody fragment of the invention. For example, if the anti-RET antibody is a RET inhibitor to be used to treat a cancerous condition, the second agent may be selected from a chemotherapeutic agent, a radioisotope, a RET-specific siRNA, a second RET-specific antibody, a small-molecule RET inhibitor, and a bone marrow-restoring agent such as G-CSF, GM-CSF, or M-CSF, or biological agents having colony-stimulating or bone marrow-restoring activity. In certain modalities, the second therapeutic agent may be an agent that helps counteract or reduce any potential side effects associated with the antibody or antigen-binding fragment of an antibody of the invention, should such side effects occur.In certain modalities, the second therapeutic agent may be useful in reducing pain associated with certain conditions characterized by pain and / or inflammation. This second agent may include a nerve growth factor (NGF) inhibitor (e.g., a small-molecule NGF antagonist or an anti-NGF antibody), aspirin or another NSAID, morphine, steroids (e.g., prednisone), an anti-Nav1.7 antibody or small-molecule inhibitor of Nav1.7, a Nav1.8 antagonist (e.g., an anti-Nav1.8 antibody or a small-molecule inhibitor of Nav1.8), or a Nav1.9 antagonist (e.g., an anti-Nav1.9 antibody or a small-molecule inhibitor of Nav1.9).9), a cytokine inhibitor (for example, an interleukin-1 (IL-1) inhibitor (such as rilonacept (IL-1 trap); Regeneron) or anakinra (KINERET®, Amgen), a small-molecule IL-1 antagonist or an anti-IL-1 antibody); an IL-18 inhibitor (such as a small-molecule IL-18 antagonist or an anti-IL-18 antibody); an IL-6 or IL-6R inhibitor (such as a small-molecule IL-6 antagonist, an anti-IL-6 antibody or an anti-IL-6 receptor antibody), caspase-1, p38, IKK1 / 2, CTLA4γ inhibitors or an opioid. It will also be appreciated that the antibodies and pharmaceutically acceptable compositions of the present invention can be used in combination therapies; that is, the antibodies and pharmaceutically acceptable compositions can be administered simultaneously, before or after one or more desired medical therapies or procedures. The particular combination of therapies (therapeutics or procedures) to be used in a combination regimen will take into account the compatibility of the desired therapies and / or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed can achieve a desired effect for the same disorder (for example, an antibody can be administered at the same time as another agent used to treat the same disorder), or they can achieve different effects (for example, control of any adverse effect).As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease or condition are appropriate for the disease or condition being treated. If it is contemplated that a small molecule RET inhibitor is to be combined with an antibody of the invention, the small molecule RET inhibitor may be selected from the group consisting of vandetanib, sorafenib, sunitinib, cabozantinib, motesanib, RPI-1, PP-1 and NVP-AST478, cediranib, (AZD2171), gefitinib, erlotinib, SU14813, vatalanib, (BAY43-9006), XL-647, XL-999, AG-013736, BIBF1120, TSU68, GW786034, AEE788, CP-547632, KRN951, CHIR258, CEP-7055, OSI-930, ABT-869, E7080, ZK304709, BAY57-9352, L- 21649, BMS582664, XL-880, XL-184, XL-820, RPI-1, PP-1 and NVP-AST478. When multiple therapies are co-administered, the doses can be adjusted accordingly, as recognized in the relevant technique. A fifth aspect of the invention provides a method for treating a disorder or condition associated with the expression, activation, or signaling of the RET tyrosine kinase receptor gene, or a rearranged form thereof, or pain associated with the disorder or condition, the method comprising administering an antibody or antigen-binding fragment of any of the anti-RET antibodies described herein together with a pharmaceutically acceptable vehicle or diluent to a patient in need. In one modality, the disorder or condition is a cancer selected from the group consisting of thyroid cancer, lung cancer, pancreatic cancer, skin cancer, breast cancer, and a blood-borne cancer. In another modality, the disorder or condition associated with the expression, activation, or signaling of the RET tyrosine kinase receptor gene, or a rearranged form thereof, is selected from the group consisting of acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, osteoarthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, neurodegenerative disorders, neuroendocrine disorders, visceral pain, acute gout, postherpetic neuralgia, diabetic neuropathy, sciatica, back pain, headache or neck pain, severe or intractable pain, breakthrough pain, post-surgical pain, dental pain, rhinitis, cancer pain, or bladder disorders. In a related aspect, the invention provides a method for inhibiting tumor growth or the proliferation of tumor cells, wherein the tumor or tumor cell expresses RET, or a rearranged form thereof, the method comprising administering an antibody or an antigen-binding fragment thereof of the invention to a patient in need. In one modality, the tumor is either a solid tumor or a blood-borne tumor. In one modality, the solid tumor is selected from the group consisting of a thyroid tumor, a lung tumor, a pancreatic tumor, a skin tumor, and a breast tumor. In one modality, the thyroid tumor is either a papillary thyroid carcinoma (PTC) or a medullary thyroid carcinoma (MTC). In one modality, medullary thyroid carcinoma is a hereditary MTC selected from the group consisting of MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC) syndrome, or in which medullary thyroid carcinoma is a sporadic MTC. In one form, the lung tumor is a lung adenocarcinoma. In one form, the lung tumor is a non-small cell lung cancer (NSCLC). In one type, the skin tumor is a melanoma. In one form, the blood-borne tumor is a leukemia. In one form, the leukemia is a chronic myelomonocytic leukemia. In a related aspect, the invention provides a method of down-modulating the expression and / or function of RET, the method comprising administering an antibody or an antigen-binding fragment thereof of the invention. In one mode, down-modulation of the RET expression and / or function results in down-regulation of a selected downstream signaling pathway from the group consisting of the RAS / RAF / ERK and PI3K pathways. In certain modes, down-modulation of the RET expression and / or function results in down-regulation of a selected signaling pathway from the group consisting of the PKC, SRC, and STAT3 pathways. crczLn / Lznz / B / Yu In one embodiment, an anti-RET antibody of the invention can interfere with, or prevent, the interaction between RET and one or more ligands belonging to the GDNF family (GDNF, neurturin, artemin, and persephin) complexed with their corresponding coreceptors (GFR1, GFR2, GFR3, and GFR4, respectively). In one embodiment, the human anti-RET antibodies described herein can interfere with or prevent the interaction of RET with the GDNF / GFRa1 complex. In a related embodiment, the human anti-RET antibodies described herein can interfere with or prevent the interaction of RET with the artemin / GFRa3 complex. In other related embodiments, the human anti-RET antibodies described herein can interfere with or prevent the interaction of RET with the neurturin / GFRa2 or persephin / GFRa4 complexes. Once activated, RET recruits a variety of signaling molecules that mediate biological responses. RET can activate several signaling pathways, such as RAS / RAF / ERK (extracellular signal-regulated kinase), phosphatidylinositol 3-kinase (PI3K) / AKT, PKC, and SRC. These signaling pathways are activated by the binding of adaptor proteins to intracellular tyrosine residues of RET phosphorylated by its own kinase activity. Accordingly, in certain aspects of the invention, an anti-RET antibody of the invention can block biological responses attributed at least in part to the activation of other signaling pathways by RET. In certain embodiments, an anti-RET antibody of the invention can interfere with signal transduction through a pathway comprising RET and RAS. In certain embodiments, an anti-RET antibody can interfere with cell proliferation, migration, or invasion, or with the phosphorylation of ERK1 / 2 (extracellular signal-regulated kinase 1 / 2). In some embodiments, an anti-RET antibody can interfere with signal transduction through a pathway comprising RET and PI3K (phosphatidylinositol-3-kinase). In certain embodiments, an anti-RET antibody can interfere with cell proliferation, migration, or invasion, or with the phosphorylation of Akt (protein kinase B). The antibody or antigen-binding fragment can be administered to the patient in combination with a second therapeutic agent suitable for treating the disease, disorder, or condition. If the disease or condition to be treated with an anti-RET antibody is a cancerous condition, the second therapeutic agent can be selected from the group consisting of a chemotherapeutic agent, a radioisotope (alone or as part of a targeted drug regimen), an antibody-drug conjugate, a small-molecule RET inhibitor, an antitumor agent, a RET-specific siRNA, and a second RET-specific antibody.If an anti-RET antibody is anticipated to treat pain associated with the cancerous condition, or to treat pain associated with other conditions that can be attributed at least in part to RET activation or signaling, the second therapeutic agent may be selected from any or more of the following: a nerve growth factor (NGF) inhibitor (e.g., a small-molecule NGF antagonist or an anti-NGF antibody), aspirin or another NSAID, morphine, steroids (e.g., prednisone), an anti-Nav1.7 antibody or a small-molecule inhibitor of Nav1.7, a Nav1.8 antagonist (e.g., an anti-Nav1.8 antibody or a small-molecule inhibitor of Nav1.8), or a Nav1.9 antagonist (e.g., an anti-Nav1.9 antibody or a small-molecule inhibitor of Nav1.9).9), a cytokine inhibitor (for example, an interleukin-1 (IL-1) inhibitor (such as crczLn / Lznz / E / Yii rilonacept (IL-1 trap”); Regeneran) or anakinra (KINERET®, Amgen), a small-molecule IL-1 antagonist or an anti-IL-1 antibody; an IL-18 inhibitor (such as a small-molecule IL-18 antagonist or an anti-IL-18 antibody); an IL-6 or IL-6R inhibitor (such as a small-molecule IL-6 antagonist, an anti-IL-6 antibody, or an anti-IL-6 receptor antibody), caspase-1, p38, IKK1 / 2, CTLA-4γ inhibitors, or an opioid. Other modalities will become evident from a review of the following detailed description. Brief description of the figures Figure 1 is a schematic diagram of the human RET receptor. Detailed description of the invention Before describing the present methods, it should be understood that this invention is not limited to the particular experimental methods and conditions described, as such methods and conditions may vary. It should also be understood that the terminology used herein is solely for the purpose of describing particular embodiments and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention pertains. As used herein, the term “approximately,” when used to refer to a particular quoted numerical value, means that the value may vary from the quoted value by no more than 1%. For example, as used herein, the expression “approximately 100” includes 99 and 101 and all intermediate values (e.g., 99.1, 99.2, 99.3, 99.4, etc.). Although any method and material similar or equivalent to those described herein may be used in the practice or testing of the present invention, preferred methods and materials are described. All publications mentioned herein are incorporated by reference in their entirety. Definitions Rearranged during transfection, also called RET, is a tyrosine kinase receptor expressed during development in a variety of tissues, including the central and peripheral nervous systems and the kidney. The RET oncogene was identified in 1985 by Takahashi et al., who reported a novel gene rearrangement with transforming activity in NIH / 3T3 cells transfected with human lymphoma DNA (See Takahashi, M., et al., (1985) Cell, 42:581-588). RET was later confirmed as an oncogene, somatically rearranged in the DNA of patients with papillary thyroid carcinoma (PTC), and subsequently designated RET / PTC. (Fusco, A. et al., (1987), Natura, 328:170-172; Grieco, M. et al., (1990), Cell, 60:557-63).The RET protein is composed of three domains: an extracellular ligand-binding domain, a hydrophobic transmembrane domain, and a cytoplasmic portion with the tyrosine kinase domain divided by a 27-amino-acid insertion (see Figure 1). There are two main isoforms of RET generated by alternative splicing. The short and long RET isoforms, which differ by 9 and 51 unrelated C-terminal amino acids, are designated RET9 crrzLn / Lznz / E / Yu and RET51, respectively. They are highly conserved across a wide range of species (Carter, MT, et al. (2001), Cytogenet Cell Genet, 95:169-76). Both isoforms exhibit transforming activity by a spot-formation assay (Rossel, M. et al. (1997), Oncogene, 14:265-75). The cDNA sequence and amino acid sequence of the RET isoform A (also known as RET51) are provided in GenBank as accession numbers NM_020975.4 and NP_066124.1, respectively, and are provided herein as SEQ ID NO: 309 and 310, respectively. The cDNA sequence and amino acid sequence of the RET C isoform (also known as RET9) are provided in GenBank as accession numbers NM_020630.4 and NP_065681.1, respectively, and are provided herein as SEQ ID NO: 311 and 312, respectively. RET, or immunogenic fragments thereof, can be used to prepare human monoclonal antibodies specific for RET. The RET protein, or fragments thereof, can be produced recombinantly using standard methods known in the art. Exemplary fusion proteins containing the RET ectodomain are shown as SEQ ID NO: 305, 306, 307, and 309. These fusion proteins can be used as immunogens or to target therapeutic agents to cells or tissues expressing RET. RET is the signaling receptor for ligands of the glial-derived neurotrophic factor (GDNF) family, comprising GDNF (See GenBank Accession No. NP_000505.1), artemin (See GenBank Accession No. Q5T4W7), neurturin (See GenBank Accession No. NM_004558) and persephin (See GenBank Accession No. AF040962). GDNF family ligands interact with and activate RET only in the presence of, or in complex with, one of the four GPI-linked coreceptors, known as GDNF family GFRα receptors (See GenBank Accession No. NP_005255.1), GFRα2 (See GenBank Accession No. NM_001495.4), GFRα3 (See GenBank Accession No. NP_001487.2), and GFRα4 (See GenBank Accession No. NM_022139 for GFRα4a and NM_145762.2 for GFRα4b) (Baloh, RH, et al. (2000), Curr Opin Neurobiol 10:103-110; Borrello, MG, et al. (2013), Expert Opin. Ther. Targets, 17(4):403-419).The primary ligands for the coreceptors GFRal, GFRRa2, GFRRa3 and GFRRa4 are GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN), respectively. The term ICso refers to the maximum median inhibitory concentration, a value that measures the effectiveness of a compound (e.g., anti-RET antibody) in inhibiting a biological or biochemical process. This quantitative measure indicates the amount required for a particular inhibitor to inhibit half of a given biological process. As used herein, the terms treat, treatment, and treats refer to the reduction in the progression of a disease, disorder, or condition attributed in part to, or associated with, the expression of RET in a cell or tissue in a subject, e.g., slowing the proliferation rate of tumor cells in patients bearing a tumor that expresses RET, when an antagonist / inhibitor antibody of the invention is administered, or reduction of pain associated with a cancerous condition, or pain associated with any other disease or condition that is caused, at least in part, by the expression of RET. As used herein, the terms prevent, prevent, and prevention refer to the inhibition of the development or onset of a disease, disorder, or condition attributed in part to or associated with RET expression in a cell or tissue in a subject, e.g., certain cancers, or the inhibition of tissue damage occurring in a patient after injury, or the inhibition or enhancement of pain associated with a disease or condition attributed in part to RET expression. The term antibody, as used herein, is intended to refer to immunoglobulin molecules composed of four polypeptide chains, two heavy chains (H) and two light chains (L) interconnected by disulfide bonds (i.e., complete antibody molecules), as well as their multimers (e.g., IgM) or their antigen-binding fragments. Each heavy chain is composed of a heavy chain variable region (HCVR or Vh) and a heavy chain constant region (composed of Ch1, Ch2, and Ch3 domains). Each light chain is composed of a light chain variable region (LCVR or Vl) and a light chain constant region (Cl). The Vh and Vl regions may be further subdivided into hypervariability regions, called complementarity-determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs).Each Vh and Vl is composed of three CDRs and four FRs arranged, from the amino terminus to the carboxyl terminus, in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the invention, the FRs of the antibody (or antigen-binding fragment thereof) may be identical to human germline sequences, or they may be modified naturally or artificially. A consensus amino acid sequence may be defined based on a simultaneous analysis of two or more CDRs. It is also possible to substitute or omit one or more CDR residues. Antibodies in which one or two CDR residues can be omitted for binding have been described in the scientific literature. Padlan et al. (1995 FASEB J. 9: 133-139) analyzed the contact regions between antibodies and their antigens, based on published crystal structures, and concluded that only about one-fifth to one-third of the CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDR residues had no amino acids in contact with an antigen (see also Vajdos et al. 2002 J Mol Biol 320:415-428). CDR residues that do not contact the antigen can be identified based on previous studies (e.g., residues H60–H65 in CDRH2 are often unnecessary), from Kabat CDR regions outside the Chothia CDRs, through molecular modeling, and / or empirically. If a CDR or residue(s) are omitted, they are typically replaced with an amino acid occupying the corresponding position in another human antibody sequence or a consensus of such sequences. Substitution positions within CDRs and the amino acids to be substituted can also be selected empirically. Empirical substitutions can be either conservative or non-conservative. The fully human monoclonal antibodies described herein may comprise one or more amino acid substitutions, insertions, and / or deletions in frame regions and / or CDRs of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be readily determined by comparing the crczLn / Lznz / E / Yii amino acid sequences described herein with available germline sequences, for example, in public antibody sequence databases.The present invention includes antibodies and antigen-binding fragments thereof, derived from any of the amino acid sequences described herein, wherein one or more amino acids within one or more frame regions and / or CDRs are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are collectively referred to herein as germline mutations). A person skilled in the art, starting with the heavy-chain and light-chain variable region sequences described herein, may readily produce numerous antibodies and antigen-binding fragments comprising one or more individual germline mutations or combinations thereof.In some embodiments, all frame and / or CDR residues within the Vh and / or Vl domains are mutated back to residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, for example, only the mutated residues located within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues located within CDR1, CDR2, or CDR3. In still other embodiments, one or more of the frame and / or CDR residues are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived).Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations within the frame and / or CDR regions, for example, where certain individual residues are mutated to the corresponding residue of a particular germline sequence, while certain other residues that differ from the original germline sequence are either retained or mutated to the corresponding residue of a different germline sequence. Once obtained, the antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as enhanced binding specificity, increased binding affinity, enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.The antibodies and antigen-binding fragments obtained in this general manner are included in the present invention. The present invention also includes fully monoclonal antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences described herein having one or more conservative substitutions. For example, the present invention includes antibodies having HCVR, LCVR, and / or CDR amino acid sequences with, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions relative to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. The term “human antibody”, as used herein, includes antibodies that have variable and constant regions derived from human germline immunoglobulin sequences. crrzLn / Lznz / E / Yi The human monoclonal antibodies (mAbs) of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), e.g., in CDRs and in particular CDR3. However, the term “human antibody” used herein is not intended to include mAbs in which CDR sequences derived from the germline of other mammalian species (e.g., a mouse, onto human framework sequences) have been grafted. The term "specifically binds" or "binds specifically to," or similar, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding can be characterized by an equilibrium dissociation constant of at least approximately 1 x 10⁶ M or less (e.g., a smaller Kd indicates a tighter binding). Methods for determining whether two molecules bind specifically are known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and similar techniques. As described herein, antibodies have been identified by surface plasmon resonance, for example, BIACORE™, which binds specifically to RET.Furthermore, multispecific antibodies that bind to the RET protein and one or more additional antigens, or a bispecific antibody that binds to two different regions of RET, are nevertheless considered specifically binding antibodies, as used herein. The term high affinity antibody refers to those mAbs that have a RET binding affinity, expressed as Kd, of at least 1CP M, at least 10-8M; preferably 10-9M; more preferably 10'10M, more preferably 10-11M, more preferably 10-12M measured by surface plasmon resonance, e.g. BIACORE™ or solution affinity ELISA. By the term deceleration rate, Koff or kd refers to an antibody that dissociates from RET, with a rate constant of 1 x 10-3s-1o less, preferably 1 x 10-4s-1o less, as determined by surface plasmon resonance, e.g., BIACORE™. The terms “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, and similar terms, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. The term antigen-binding portion of an antibody, or antibody fragment, as used herein, refers to one or more fragments of an antibody that retain the ability to bind to RET. The specific modalities, antibodies, or antibody fragments of the invention can be conjugated with a therapeutic portion (immunoconjugate or antibody-drug conjugate), such as a small-molecule RET inhibitor, an antitumor agent, a radioisotope, a growth factor, a bone marrow restorative agent, or a colony-stimulating factor, or any other therapeutic portion useful for treating a disease, disorder, or condition associated with RET expression, such as cancer or damaged tissue. An isolated antibody, as used herein, is intended to refer to a crczLn / Lznz / E / Yii antibody that is substantially free of other antibodies (Abs) having different antigenic specificities (e.g., an isolated antibody that binds specifically to RET, or a fragment thereof, is substantially free of Abs that bind specifically to antigens other than RET). A blocking antibody or a neutralizing antibody, as used herein (or an antibody that neutralizes RET activity), is intended to refer to an antibody whose binding to RET results in the inhibition of at least one biological activity of RET, such as cell signaling. For example, an antibody of the invention may help block the binding of RET to its ligand, or to one of the GFRα coreceptors, or prevent or treat a disease associated with RET expression. Alternatively, an antibody of the invention may demonstrate the ability to improve at least one symptom of the disease or condition associated with RET expression.This inhibition of RET biological activity can be assessed by measuring one or more indicators of RET biological activity using one or more of several standard in vitro assays (such as any of the assays described herein) or in vivo assays known in the art (e.g., animal models to observe the inhibition of tumor cell growth in vivo) after administration of one or more of the antibodies described herein. The term surface plasmon resonance, as used herein, refers to an optical phenomenon that enables the analysis of biomolecular interactions in real time by detecting alterations in protein concentrations within a biosensor array, for example, using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). The term Kd, as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction. The term epitope refers to an antigenic determinant that interacts with a specific antigen-binding site on the variable region of an antibody molecule known as a paratope. A single antigen can have more than one epitope. Thus, different antibodies can bind to different areas on an antigen and may have different biological effects. The term epitope also refers to a site on an antigen to which B and / or T cells respond. It also refers to a region of an antigen that is bound by an antibody. Epitopes can be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and contain residues that directly contribute to the affinity of the interaction. Epitopes can also be conformational, meaning they are composed of nonlinear amino acids.In certain modalities, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain modalities, they may have specific three-dimensional structural features and / or specific charge characteristics. The term “substantial identity” or “substantially identical,” when referring to a nucleic acid or a fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is identity of the crczLn / Lznz / E / Yii nucleotide sequence in at least approximately 90%, and very preferably at least 95%, 96%, 97%, 98%, or 99% of the nucleotide bases, as measured by any well-known sequence identity algorithm, such as FASTA, BLAST, or GAP, as described below. A nucleic acid molecule that has substantial identity with a reference nucleic acid molecule may, in certain cases, encode a polypeptide having an amino acid sequence that is the same as, or substantially similar to, the polypeptide encoded by the reference nucleic acid molecule. Applied to polypeptides, the term “substantial similarity” or “substantially similar” means that two peptide sequences, when optimally aligned, for example, using GAP or BESTFIT programs with gap weighting by default, share at least 90° of sequence identity, and very preferably at least 95°, 98°, or 99° of sequence identity. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is replaced by another amino acid residue that has a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein.In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percentage or degree of sequence similarity can be further adjusted to correct for the conservative nature of the substitution. The means of making this adjustment are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference.Examples of amino acid groups that have side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate; and 7) sulfur-containing side chains: cysteine and methionine. Preferred groups for conservative amino acid substitution are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change that has a positive value in the probability logarithm matrix PAM250 described by Gonnet et al. (1992) Science 256:1443 45, incorporated herein by reference.A “moderately conservative” replacement is any change that has a non-negative value in the PAM250 probability logarithm matrix. Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software compares similar sequences using similarity measurements assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, the GCG software contains programs such as GAP and BESFIT that can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild-type protein and a mutein from the same species. See, for example, GCG, version 6.1. Polypeptide sequences can also be compared using FASTA with default or recommended parameters, a program in GCG, version 6.1.FASTA (e.g., FASTA2 and FASTA3) provides alignments and percentage sequence identity of the regions of best overlap between the query and search sequences (Pearson (2000) supra). Another preferred algorithm when comparing a sequence of the invention with a database containing a large number of sequences from different organisms is the BLAST computer program, especially BLASTP or TBLASTN, using the default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each incorporated herein by reference. In specific embodiments, the antibody or antibody fragment for use in the method of the invention may be monospecific, bispecific, or multispecific. Multispecific antibodies may be specific for different epitopes of a target polypeptide or may contain antigen-binding domains specific for epitopes of more than one target polypeptide. An exemplary bispecific antibody form that may be used in the context of the present invention involves the use of a first immunoglobulin (Ig) Ch3 domain and a second Ig Ch3 domain, wherein the first and second Ig Ch3 domains differ from each other by at least one amino acid, and wherein at least one amino acid difference reduces the binding of the bispecific antibody to Protein A compared to a bispecific antibody lacking the amino acid difference.In one embodiment, the first Ch3 domain of Ig binds to protein A, and the second Ch3 domain of Ig contains a mutation that reduces or abolishes binding to protein A, such as an H95R modification (according to exon numbering IMGT; H435R according to EU numbering). The second Ch3 may further comprise a Y96F modification (according to IMGT; Y436F according to EU). Additional modifications that may be found within the second Ch3 include: D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of lgG1 mAbs; N44S, K52N and V82I (IMGT; N384S, K392N and V422I by EU) in the case of lgG2 mAbs; and Q15R, N44S, K52N, V57M, R69K, E79Q and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q and V422I by EU) in the case of lgG4 mAbs. Variations in the bispecific antibody format described above are contemplated within the scope of the present invention. The term therapeutically effective quantity refers to a quantity that produces the desired effect for which it is administered. The exact quantity will depend on the purpose of the treatment and will be determined by an expert in the technique using known techniques (see, for example, Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding). General Description Reassorted during transfection, also known as RET, is a tyrosine kinase receptor expressed during development in a variety of tissues, including the peripheral and central nervous systems and the kidney. (Arighi, E. et al. (2005), Cytokine Growth Factor Rev 16:441-67; Borrello, MG, et al., (2013), Expert Opin. Ther. Targets, 17(4): 403-419). The RET oncogene was identified in 1985 by Takahashi et al., who reported a novel gene rearrangement with transforming activity in NIH / 3T3 cells transfected with human lymphoma DNA (See Takahashi, crczLn / Lznz / E / Yii M., et al., (1985) Cell, 42:581-588). RET was later confirmed to be an oncogene, somatically rearranged in the DNA of patients with papillary thyroid carcinoma (PTC), and subsequently designated RET / PTC. (Fusco, A. et al., (1987), Nature, 328:170-172; Grieco, M. et al., (1990), Cell, 60:557-63). The RET protein is composed of three domains: an extracellular ligand-binding domain, a hydrophobic transmembrane domain, and a cytoplasmic portion with the tyrosine kinase domain divided by a 27-amino-acid insertion (see Figure 1). There are two main isoforms of RET generated by alternative splicing. The short and long RET isoforms, which differ by 9 and 51 unrelated C-terminal amino acids, are named RET9 and RET51, respectively. They are highly conserved across a wide range of species. (Carter, MT, et al. (2001), Cytogenet Cell Genet, 95:16976).Both isoforms show transforming activity by means of a focus formation assay (Rossel, M. et al. (1997), Oncogene, 14:265-75). Genetic alterations in RET have been shown to be involved in the etiology of thyroid cancers, and more recent data suggest that RET is also involved in lung adenocarcinomas (Viglietto, G. et al. (1995), Oncogene, 11:1207-10; Fischer, AH, et al., (1998), Am J Pathol. 153:1443-50). Other studies suggest that RET may be involved in other tumors, such as breast, pancreatic, leukemia, and melanoma tumors (Ballerini, P. et al., (2012), Leukemia, 26:2384-9; Sawai, H. et al. (2005), 65(24)41536-44; Narita, N. et al., (2009), Oncogene, 28:3058-68). Vandetanib (ZD6474, CAPRELSA®, AstraZeneca) is an orally available aminoquinazoline compound that was initially developed as a VEGFR2 inhibitor but was later found to be active against RET, VEGFR3, EGFR, and PDGFR. Vandetanib is currently approved by the FDA and EMA for advanced and metastatic medullary thyroid carcinoma (Wells, SA, et al., (2012), J. Clin. Oncol. 30:134-41). Sorafenib (BAY43-9006, NEXAVAR®, Bayer Pharmaceuticals) is a bisarylurea compound initially developed to target the serine / threonine kinase BRAF, but was later found to be a potent agent against Flt-3, VEGFR1-3, PDGFR, c-kit, and RET (Wilhelm, S. et al., (2006), Nat Rev Drug Discov, 5:835-44). Sorafenib was approved by the FDA for advanced liver and kidney cancers. Sunitinib (SU11248, SUTENT®, Pfizer) is an indolinone compound that primarily targets the kinases VEGFR2, PDGFR, c-kit, FLT3, and RET (Chow, LQ, et al., (2007), J. Clin. Oncol. 25:884-96). Sunitinib was approved by the FDA for patients with imatinib-resistant GIST, as well as for advanced pancreatic neuroendocrine tumors and renal cell carcinoma. Cabozantinib (Cometriq, formerly known as XL-184, Exelixis) is a small-molecule multikinase inhibitor that targets MET, VEGFR2, and RET. It is currently in clinical trials in a wide range of tumor types, including medullary thyroid cancer, prostate cancer, ovarian cancer, non-small cell lung cancer (NSCLC), hepatocellular, renal cell, and breast cancer, as well as melanoma and glioblastoma (Zhang, Y. et al., (2010), IDrugs 13:112-21). Another RET-targeting agent in clinical development is motesanib (AMG-706, Amgen), which is a multikinase inhibitor that targets VEGFR1-3, Flt3, Kit, PDGFR, and RET. Other RET inhibitors in preclinical development include RPI-1, which is an indoline compound; PPceczLn / Lznz / E / Yu 1, which is a pyrazolopyrimidine compound active on RET and Src; and NVP-AST478, which is a biphenylurea compound that has potent anti-RET kinase activity in vitro and in vivo (Cuccuru, G. et al. (2004), J Nati Cancer Inst 96:1006-14). However, a problematic aspect of the RET inhibitors mentioned above is that they are not specific to RET; that is, they appear to act through multiple mechanisms and, as such, could potentially exert other adverse effects in vivo. For example, some of the inhibitors mentioned above induce adverse events such as hypertension and QTc interval prolongation. Therefore, the non-selective profile of these agents may limit the therapeutic window. It would be beneficial to identify agents, such as an anti-RET antibody, that selectively bind to RET, which could result in superior clinical efficacy with a more favorable safety profile. Consequently, there remains a need for effective therapies against RET-driven tumors, and furthermore, a need to identify a RET-specific agent to prevent and treat other diseases, disorders, or conditions associated with RET expression without the adverse side effects associated with the agents described above. Such specificity and efficacy can be achieved through the use of an anti-RET antibody, such as those described herein. In certain embodiments, the antibodies of the invention are obtained from mice immunized with a primary immunogen, such as a complete human RET protein, or with a recombinant form of the protein, or a fragment thereof, or with a fusion protein containing the extracellular / ecto domain of human RET. (See GenBank accession number NP_066124.1 (SEQ ID NO: 310) or GenBank accession number NP_065681.1 (SEQ ID NO: 312), or a recombinantly produced RET fusion protein (See SEQ ID NO: 305, 306, 307 and 313), followed by immunization with a secondary immunogen (purified human RET protein), or with an immunogenically active fragment of the RET protein, such as the ectodomain of RET. The immunogen can be DNA encoding the human RET protein (See GenBank accession number NM 020975.4 and SEQ ID NO: 309 for isoform A; or GenBank accession number NM_020630.4 and SEQ ID NO: 311 for isoform C) or an active fragment thereof. The immunogen may be derived from the extracellular domain of the RET protein, encompassing amino acid residues 1-635 of any of the SEQ ID NO: 305, 307, 310, 312, and 313 (including the signal sequence); or from amino acid residue 1-636 of SEQ ID NO: 306 (including the signal sequence). An immunogen may be derived from a fragment of any of the RET protein regions listed above. The full-length amino acid sequence of RET51 is shown as SEQ ID NO: 310 and is also shown in GenBank accession number NP_066124.1. The full-length amino acid sequence of RET9 is shown as SEQ ID NO: 312 and is also shown in GenBank accession number NP_065681.1. The exemplary immunogens may be the recombinant constructs shown in SEQ ID NO: 307 or 313. In certain formulations, antibodies that bind specifically to RET can be prepared using fragments of the aforementioned regions, or peptides that extend beyond the designated crczLn / Lznz / E / Yu regions by approximately 5 to approximately 20 amino acid residues from either or both of the N- or C-terminus regions described herein. In certain formulations, any combination of the aforementioned regions or fragments thereof can be used in the preparation of RET-specific antibodies. In certain formulations, any or more of the aforementioned RET regions, or fragments thereof, can be used to prepare monospecific, bispecific, or multispecific antibodies. Antigen-binding fragments of antibodies Unless specifically stated otherwise, the term antibody, as used herein, is to be understood to include antibody molecules comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., complete antibody molecules) as well as antigen-binding fragments thereof. The terms “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. The terms “antigen-binding portion” of an antibody or antibody fragment, as used herein, refer to one or more fragments of an intact antibody that retain the ability to bind specifically to RET.An antibody fragment may include a Fab fragment, an F(ab')2 fragment, an Fv fragment, a dAb fragment, a fragment containing a CDR, or an isolated CDR. Antigen-binding fragments of an antibody may be derived, for example, from whole antibody molecules, using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of the DNA encoding the variable and optionally constant domains of the antibody. Such DNA is known or readily available, for example, from commercial sources, DNA collections (including, for instance, phage-antibody libraries), or it may be synthesized.DNA can be sequenced and manipulated chemically or using molecular biology techniques, for example, to arrange one or more variable or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc. Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv molecules (scFv); (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity-determining region (CDR) such as a CDR3 peptide), or a restricted FR3-CD3-FR4 peptide. Other manipulated molecules include domain-specific antibodies, single-domain antibodies, suppressed-domain antibodies, chimeric antibodies, CDR-grafted antibodies, bivalent fragments, trivalent fragments, tetravalent fragments, mini-antibodies, and nano-antibodies (e.g., monovalent nano-antibodies, bivalent nano-antibodies, etc.).), small modular immunopharmaceutical agents (SMIRs) and shark IgNAR variable domains, are also encompassed in the expression “antigen-binding fragment” used herein. crczLn / Lznz / E / Yii An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain can be of any size or amino acid composition and will generally comprise at least one CDR, which is adjacent to or framed with one or more frame sequences. In antigen-binding fragments that have a Vh domain associated with a Vl domain, the Vh and Vl domains can be positioned relative to each other in any suitable arrangement. For example, the variable region may be dimeric and contain Vh-Vh, Vh-Vl, or Vl-Vl dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric Vh or Vl domain. In certain embodiments, the antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the present invention include: (i) Vh-Ch1; (ii) Vh-Ch2; (iii) Vh-Ch3; (iv) Vh-Ch1-Ch2; (v) Vh-Ch1-Ch2-Ch3; (vi) Vh-Ch2-Ch3; (vii) Vh-Cl; (viii) Vl-Ch1; (x) Vl-Ch2; (x) Vl-Ch3; (xi) Vl-Ch1-Ch2; (xii) Vl-Ch1-Ch2-Ch3; (xiii) Vl-Ch2-Ch3; and (xiv) Vl-Cl. In any configuration of variable and constant domains, including any of the exemplary configurations mentioned above, the variable and constant domains may be directly linked to each other or may be linked by means of a complete or partial hinge or linking region.A hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60, or more) amino acids, resulting in a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, an antigen-binding fragment of an antibody of the present invention may comprise a homodimer or heterodimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with each other and / or with one or more Vh or Vl monomeric domains (e.g., via disulfide bond(s)). Like complete antibody molecules, antigen-binding fragments can be single-specific or multi-specific (e.g., bi-specific). A multi-specific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, where each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multi-specific antibody format, including the exemplary bi-specific antibody formats disclosed herein, can be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art. Preparation of human antibodies Methods for generating human antibodies in transgenic mice are known in the art. Any of these known methods can be used in the context of the present invention to produce human antibodies that bind specifically to RET. Using VELOCIMMUNE® technology (see, for example, US 6,596,541, Regeneran Pharmaceuticals, VELOCIMMUNE®) or any other known method for generating monoclonal antibodies, chimeric antibodies with high affinity for RET are initially isolated. These antibodies have a human crczLn / Lznz / E / Yii variable region and a mouse constant region. VELOCIMMUNE® technology involves generating a transgenic mouse with a genome comprising human heavy- and light-chain variable regions operatively linked to mouse endogenous constant region loci, such that the mouse produces an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation. The DNA encoding the antibody's heavy- and light-chain variable regions is isolated and operatively linked to the DNA encoding the human heavy- and light-chain constant regions.Then, the DNA is expressed in a cell capable of expressing the fully human antibody. Typically, a VELOCIMMUNE® mouse is challenged with the antigen of interest, and lymphocytes (such as B cells) are retrieved from the mice expressing antibodies. The lymphocytes can be fused with a myeloma cell line to prepare immortal hybridoma cell lines, and these hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. DNA encoding the variable regions of the heavy and light chains can be isolated and joined to desirable isotypical constant regions of the heavy and light chains. Such an antibody protein can be produced in a cell, such as a CHO cell. Alternatively, DNA encoding antigen-specific chimeric antibodies or the variable domains of the light and heavy chains can be isolated directly from antigen-specific lymphocytes. Initially, high-affinity chimeric antibodies are isolated, each possessing a human variable region and a mouse constant region. As described in the experimental section below, the antibodies are characterized and selected for desirable traits, including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody of the invention, e.g., wild-type or modified IgG1 or IgG4. While the selected constant region may vary according to the specific application, the high-affinity antigen-binding and target specificity characteristics reside in the variable region. In certain embodiments, the antibodies of the present invention possess affinities (Kd) ranging from approximately 1.0 x 10⁻⁷ M to approximately 1.0 x 10⁻¹² M, when measured by binding to antigen immobilized in solid or solution phase. The mouse constant regions are replaced with desired human constant regions to generate the fully human antibodies of the invention. While the selected constant region may vary according to the specific application, the high-affinity antigen-binding and target-specific characteristics reside in the variable region. Bioequivalents The anti-RET antibodies and antibody fragments of the present invention comprise proteins having amino acid sequences that vary from those of the described antibodies, but which retain the ability to bind to RET. These variant antibodies and antibody fragments comprise one or more amino acid additions, deletions, or substitutions when compared to the original crczLn / Lznz / E / Yii sequence, but exhibit biological activity that is essentially equivalent to that of the described antibodies. Likewise, the DNA sequences encoding antibodies of the present invention comprise sequences that include one or more nucleotide additions, deletions, or substitutions compared to the described sequence, but which encode an antibody or antibody fragment that is essentially bioequivalent to an antibody or antibody fragment of the invention. Two antigen-binding proteins, or antibodies, are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not differ significantly when administered at the same molar dose under similar experimental conditions, whether in single or multiple doses. Some antibodies will be considered pharmaceutical equivalents or alternatives if they are equivalent in the extent of absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and reflected in the labeling, are not essential for achieving effective body concentrations of the drug in, for example, chronic use, and are considered medically insignificant for the particular drug being studied. In one modality, two antigen-binding proteins are bioequivalent if there are no clinically significant differences in their safety, purity, and potency. In one modality, two antigen-binding proteins are bioequivalent if a patient can switch one or more times between the reference product and the biologic product without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or decreased efficacy, compared to continuous therapy without such a switch. In one modality, two antigen-binding proteins are bioequivalent if they both act through a common mechanism or mechanisms of action for the condition or conditions of use, to the extent that such mechanisms are known. Bioequivalence can be demonstrated using in vivo and / or in vitro methods. Bioequivalence measures include, for example, (a) an in vivo test in humans or other mammals, in which the concentration of the antibody or its metabolites in blood, plasma, serum, or other biological fluid is measured over time; (b) an in vitro test that has been correlated with and is reasonably predictive of in vivo bioavailability data in humans; (c) an in vivo test in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured over time; and (d) a well-controlled clinical trial that establishes the safety, efficacy, bioavailability, or bioequivalence of an antibody. Bioequivalent variants of the antibodies of the invention can be constructed, for example, by performing various residue or sequence substitutions or by deleting terminal or internal residues or sequences not required for biological activity. For example, cysteine residues not essential for biological activity can be removed or replaced with other amino acids to avoid the formation of unnecessary or incorrect intramolecular disulfide bonds after renaturation. In other contexts, bioequivalent antibodies can include antibody variants comprising amino acid changes that modify the glycosylation characteristics of the antibodies, for example, ceczLn / Lznz / E / Yu mutations that eliminate or suppress glycosylation. Anti-RET antibodies comprising Fe variants According to certain embodiments of the present invention, anti-RET antibodies are provided comprising an Fe domain with one or more mutations that enhance or diminish the antibody's binding to the FcRn receptor, for example, at acidic pH compared to neutral pH. For instance, the present invention includes anti-RET antibodies comprising a mutation in the Ch2 or Ch3 region of the Fe domain, wherein the mutation(s) increase the affinity of the Fe domain to the FcRn in an acidic environment (for example, in an endosome where the pH ranges from approximately 5.5 to approximately 6.0). Such mutations may result in an increased serum half-life of the antibody when administered to an animal.Non-limiting examples of these Fe modifications include, for example, a modification at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or a modification at position 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y); or a modification at position 250 and / or 428; or a modification in position 307 or 308 (for example, 308F, V308F), and 434. In one embodiment, the modification comprises a 428L modification (e.g., M428L) and 434S (e.g., N434S); a 428L, 259I modification (e.g., V259I), and 308F modification (e.g., V308F); a 433K modification (e.g., H433K) and a 434 modification (e.g., 434Y); a 252, 254, and 256 modification (e.g., 252Y, 254T, and 256E); a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 amendment and / or a 308 amendment (e.g., 308F or 308P). For example, the present invention includes anti-RET antibodies comprising an Fe domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T, and 256E (e.g., M252Y, S254T, and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the above Fe domain mutations and other mutations in the variable domains of the antibody are contemplated within the scope of the present invention. Biological characteristics of antibodies In general, the antibodies of the present invention can function by binding to RET and, in doing so, act to block or prevent RET activation and / or signaling. The antibodies of the present invention can also function by binding to RET and, in doing so, interfering with, or preventing, the interaction or binding of RET with one or more members of the GDNF family complexed with their corresponding coreceptors, for example, GDNF / GFRa1, neurturin / GFRa2, artemin / GFRa3, or persephin / GFRa4. Based on the fact that the tumorigenic potential of RET has been established in humans, an antagonistic antibody that binds specifically to RET may demonstrate a beneficial effect in inhibiting tumor cell growth in patients suffering from a cancerous condition. In certain embodiments, the antibodies of the present invention can function by blocking or inhibiting RET activity by binding to any region or fragment of the full-length protein, the amino acid sequence of which is shown in SEQ ID NO: 310 (RET51), also shown as crrzLn / Lznz / E / Yi under GenBank accession number NP 066124.1 and in SEQ ID NO: 312 (RET9), and also shown under GenBank accession number NP_065681.1. The antibodies can also bind to any region found in SEQ ID NO: 310 or 312, or to a fragment found within SEQ ID NO: 310 or 312. In one embodiment, the invention provides a fully human monoclonal antibody or an antigen-binding fragment thereof that binds to the RET protein, wherein the antibody or fragment thereof exhibits one or more of the following characteristics: (a) is a fully human antibody; (b) exhibits a Kd ranging from approximately 1.0 X 10-7M to approximately 1.0 X 1012M measured by surface plasmen resonance; (c) inhibits or blocks the binding or interaction of RET with one or more ligands belonging to the GDNF family (GDNF, neurturin, artemin and persephin) complexed with their corresponding coreceptors (GFR1, GFRRa2, GFRRa3 and GFRRa4, respectively); (d) inhibits RET signaling mediated by one or more GDNF family ligands selected from GDNF, neurturin, artemin, and persephin; (e) enhances internalization / degradation by RET after antibody binding to RET receptor; (f) comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290; or (g) comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298. Certain anti-RET antibodies of the present invention are capable of binding to the RET protein and inhibiting RET-associated activation and / or signaling. By doing so, the antibodies can inhibit the growth of tumors that depend on RET signaling for growth. Such antagonistic anti-RET antibodies can be used alone to treat a cancerous condition or as adjunctive therapy with any other anticancer agent, such as a small-molecule chemotherapeutic agent, radiotherapy, or a bone marrow regenerator. In certain modalities, anti-RET antibodies may be able to inhibit multiple signaling pathways, including the RAS / RAF pathway, which leads to the activation of mitogen-activated protein kinases (MAPKs) ERK1 and ERK2 (Trupp, M. et al., (1999), J Biol. Chem. 274:20885-94; Santoro, M. et al., (1994), Mol. Cell Biol. 14:663-75; van Weering, DHJ, et al. (1995), 11:2207-14; Worby, CA, et al., (1996), J Biol Chem, 271:23619-22), phosphatidylinositol 3-kinase (PI3K), resulting in activation of the serine / threonine kinase Akt (Trupp, M. et al., (1999), J Biol. Chem. 274:20885-94; van Weering, DHJ, (1997), J Biol Chem 272:249-54; Segouffin-Cariou, C., et al, (2000), 275:3568-76; Maeda, K. et al, (2004), 323: 345-54). Examples 4 and 5 illustrate, respectively, exemplary in vitro assays for measuring the ability of the anti-RET antibodies of the invention to block RET binding to the GFRα1 / GDNF co-complex and in vitro assays for measuring the effect of the antibodies on RET signaling, activation, or internalization. In Example 3, the binding affinities and kinetic constants of the human anti-RET antibodies were determined by surface plasmon resonance, and the measurements were performed on a Biacore 4000 or T200 instrument. In Example 4, the ability of the antibodies to block RET binding to the GFRα1 / GDNF co-complex was tested using a competitive sandwich ELISA. Example 5 demonstrates the ability of the antibodies of the invention to inhibit ligand-dependent RET signaling in a serum response factor (SRE) luciferase reporter assay.More particularly, the data presented in Example 5 show that the anti-RET antibodies of the invention exhibit a range of inhibitory activity on RET signaling in the presence of glial family ligands, GDNF, and artemin. Epitope mapping and related technologies Various techniques known to experts in the field can be used to determine whether an antibody interacts with one or more amino acids within a polypeptide or protein. Exemplary techniques include, for instance, a routine cross-block assay such as that described by Antibodies, Harlow, and Lañe (Coid Spring Harbor Press, Coid Spring Harbor, NY). Other methods include alanine scanning mutational analysis, peptide transfer analysis (Reineke (2004) Methods Mol Biol 248:443-63), crystallographic studies of peptide cleavage analysis, and NMR analysis. In addition, methods such as epitope cleavage, epitope extraction, and chemical modification of antigens can be employed (Tomer (2000) Protein Science 9: 487-496). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen / deuterium exchange detected by mass spectrometry.In general terms, the hydrogen / deuterium exchange method involves labeling the protein of interest with deuterium, followed by binding the antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water, and the exchangeable protons within the amino acids protected by the antibody complex undergo reverse deuterium-to-hydrogen exchange at a slower rate than the exchangeable protons within amino acids not part of the interface. As a result, the amino acids that are part of the protein / antibody interface retain deuterium and thus exhibit a relatively greater mass compared to the amino acids not included in the interface.After antibody dissociation, the target protein is subjected to mass spectrometry and protease cleavage analysis, revealing the deuterium-labeled residues that correspond to the specific amino acids with which the antibody interacts. See, for example, Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal. Chem. 73256A-265A. The term epitope refers to a site on an antigen to which B and / or T cells respond. B cell epitopes can form from both contiguous and non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon exposure to denaturing solvents, while epitopes formed by tertiary folding are typically lost upon treatment with the denaturing solvents crczLn / Lznz / E / Yii. An epitope typically includes at least 3, and more commonly at least 5 or 8 to 10 amino acids in a unique spatial conformation. Modification-assisted profiling (MAR), also known as antigen structure-based antibody profiling (ASAR), is a method that categorizes a large number of monoclonal antibodies (mAbs) directed against the same antigen according to the similarities in each antibody's binding profile to chemically or enzymatically modified antigen surfaces (US patent 2004 / 0101920, which is incorporated herein specifically by reference in its entirety). Each category can reflect a unique epitope, distinct from or partially overlapping with the epitope represented by another category. This technology allows for the rapid filtering of genetically identical antibodies, so that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP can facilitate the identification of rare hybridoma clones that produce mAbs with the desired characteristics.MAP can be used to classify the antibodies of the invention into groups of antibodies that bind to different epitopes. The present invention includes anti-RET antibodies that bind to the same epitope as any of the specific exemplary antibodies described herein in Table 1. Furthermore, the present invention also includes anti-RET antibodies that compete for binding to RET or a fragment thereof with any of the specific exemplary antibodies described herein in Table 1. It can be easily determined whether an antibody binds to the same epitope or competes for binding with a reference anti-RET antibody using routine methods known in the field. For example, to determine whether a test antibody binds to the same epitope as a reference RET antibody of the invention, the reference antibody is allowed to bind to a RET protein or peptide under saturation conditions. The ability of a test antibody to bind to the RET molecule is then evaluated. If the test antibody is able to bind to RET after saturation binding with the reference anti-RET antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-RET antibody.On the other hand, if the test antibody is not able to bind to the RET molecule after saturation binding with the reference anti-RET antibody, then the test antibody can bind to the same epitope as the epitope bound by the reference anti-RET antibody of the invention. To determine whether an antibody competes for binding with a reference anti-RET antibody, the binding methodology described above is performed in two approaches: In the first approach, the reference antibody is allowed to bind to a RET molecule under saturation conditions, followed by an assessment of the test antibody's binding to the RET molecule. In the second approach, the test antibody is allowed to bind to a RET molecule under saturation conditions, followed by an assessment of the reference antibody's binding to the RET molecule. If, in both approaches, only the first (saturating) antibody is able to bind to the RET molecule, then it is concluded that the test antibody and the reference antibody compete for binding to RET.As a person with ordinary technical knowledge will appreciate, an antibody competing for binding with a reference antibody may not necessarily bind to the epitope identical to that of the reference crczLn / Lznz / E / Yii antibody, but may spherically block the binding of the reference antibody by binding to an overlapping or adjacent epitope. Two antibodies bind to the same epitope or to overlapping epitopes if each competitively inhibits (blocks) the binding of the other to the antigen. That is, a 1, 5, 10, 20, or 100-fold excess of one antibody inhibits the binding of the other by at least 50%, but preferably by 75%, 90%, or even 99%, as measured in a competitive binding assay (see, for example, Junghans et al., Cancer Res. 1990 50:1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate the binding of one antibody also reduce or eliminate the binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate the binding of one antibody also reduce or eliminate the binding of the other. Further routine experimentation (e.g., peptide binding and mutation analysis) can then be performed to confirm whether the observed lack of binding of the test antibody is indeed due to binding to the same epitope as the reference antibody or whether steric blocking (or another phenomenon) is responsible for the observed lack of binding. Experiments of this type can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the field. Immunoconjugates The invention encompasses a human RET monoclonal antibody conjugated to a therapeutic portion (immunoconjugate), such as an agent capable of inhibiting the proliferation of tumor cells or improving at least one symptom associated with a RET-associated condition, such as cancer. This agent may be a second antibody other than RET, an antitumor chemotherapeutic agent, or a radioisotope that, when directed against a RET-expressing tumor cell, kills the tumor cell. The type of therapeutic portion that can be conjugated to the anti-RET antibody will depend on the condition to be treated and the desired therapeutic effect to be achieved.Alternatively, if the desired therapeutic effect is to treat the sequelae or symptoms associated with RET expression by certain tissues, or any other condition resulting from RET expression, such as, but not limited to, cancer, it may be advantageous to conjugate an agent suitable for treating the sequelae or symptoms of the condition, or for alleviating any side effects of the antibodies of the invention. Examples of suitable agents for forming immunoconjugates are known in the art; see, for example, WO 05 / 103081. Multispecific antibodies The antibodies of the present invention may be monospecific, bispecific, or multispecific. Multispecific antibodies may be specific for different epitopes of a target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, for example, Tutte et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244. The antibodies of the present invention may be bound to or co-expressed with another functional molecule, for example, another peptide or protein. For example, an antibody or a fragment thereof may be functionally bound (for example, by chemical docking, genetic fusion, non-covalent association, or otherwise) to one or more molecular entities, such as another antibody or antibody fragment, to produce a bispecific or multispecific antibody with a second binding specificity. An exemplary bispecific antibody form that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) Ch3 domain and a second Ig Ch3 domain, wherein the first and second Ig Ch3 domains differ from each other by at least one amino acid, and wherein the difference of at least one amino acid reduces the binding of the bispecific antibody to protein A compared to a bispecific antibody lacking the amino acid difference. In one embodiment, the first Ig Ch3 domain binds to protein A, and the second Ig Ch3 domain contains a mutation that reduces or eliminates binding to protein A, such as an H95R modification (according to exon numbering IMGT; H435R according to EU numbering). The second Ch3 domain may further comprise a Y96F modification (according to IMGT; Y436F according to EU numbering).Additional modifications that may be found within the second Ch3 include: D16E, L18M, N44S, K52N, V57M and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M and V422I by EU) in the case of lgG1 antibodies; N44S, K52N and V82I (IMGT; N384S, K392N and V422I by EU) in the case of lgG2 antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q and V422I by EU) in the case of lgG4 antibodies. Variations in the bispecific antibody format described above are contemplated within the scope of the present invention. Therapeutic administration and formulations The invention provides therapeutic compositions comprising anti-RET antibodies or antigen-binding fragments thereof of the present invention. The therapeutic compositions according to the invention are administered with suitable vehicles, excipients, and other agents incorporated into the formulations to provide improved transfer, delivery, tolerability, and the like. A multitude of suitable formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, vesicle-containing lipids (cationic or anionic) (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, carbowax emulsions (polyethylene glycols of various molecular weights), semisolid gels, and semisolid mixtures containing carbowax. See also Powell et al. Compendium of excipients for parenteral formulations PDA (1998) J Pharm Sci Technol 52:238-311. The dosage of each of the antibodies of the invention may vary depending on the age and size of the recipient, the target disease, conditions, route of administration, and similar factors. When the antibodies of the present invention are used to treat a RET-associated disease or condition in a patient, or to treat one or more symptoms associated with a condition dependent on RET activation or signaling, such as certain RET-expressing tumors in a patient, or to lessen the severity of the disease, it is advantageous to administer each of the antibodies of the present invention intravenously or subcutaneously, normally in a single dose of approximately crrzLn / Lznz / E / Yii 0.01 to approximately 30 mg / kg of body weight, more preferably from approximately 0.1 to approximately 20 mg / kg of body weight, or from approximately 0.1 to approximately 15 mg / kg of body weight, or from approximately 0.02 to approximately 7 mg / kg of body weight, from approximately 0.03 to approximately 5 mg / kg of body weight, or from approximately 0.05 to approximately 3 mg / kg of body weight, or approximately 1 mg / kg of body weight, or approximately 3.0 mg / kg of body weight, or approximately 10 mg / kg of body weight, or approximately 20 mg / kg of body weight. Multiple doses may be administered as required. The frequency and duration of treatment may be adjusted depending on the severity of the condition. In certain modalities, the antibodies or antigen-binding fragments thereof of the invention may be administered as an initial dose of at least approximately 0.1 mg to approximately 800 mg, approximately 1 mg to approximately 600 mg, approximately 5 mg to approximately 300 mg, or approximately 10 mg to approximately 150 mg, to approximately 100 mg, or to approximately 50 mg. In certain formulations, the initial dose may be followed by the administration of a second or a plurality of subsequent doses of the antibodies or antigen-binding fragments thereof in an amount that may be approximately equal to or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days; at least 1 week; at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks. Several delivery systems are known and can be used to administer the pharmaceutical composition of the invention, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, and receptor-mediated endocytosis (see, for example, Wu et al. (1987) J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (for example, oral mucosa, nasal mucosa, rectal and intestinal mucosa, etc.), and can be administered in conjunction with other biologically active agents. Administration can be systemic or local.It can be administered as an aerosol formulation (See US2011 / 0311515 and US2012 / 0128669). The administration of agents useful for the treatment of respiratory diseases by inhalation is becoming increasingly accepted (See AJ Bitonti and JA Dumont, (2006), Adv. Drug Deliv. Rev, 58:1106-1118). In addition to being effective in the treatment of local lung disease, this delivery mechanism may also be useful for the systemic administration of antibodies (See Maillet et al. (2008), Pharmaceutical Research, Vol. 25, No. 6, 2008). The pharmaceutical composition can also be administered in a vesicle, in particular a liposome (see, for example, Langer (1990) Science 249:1527-1533). In certain situations, the pharmaceutical composition can be administered via a controlled-release system. In one modality, a pump can be used. In another modality, polymeric materials can be used. In yet another modality, a controlled-release system can be placed in close proximity to the target of the composition, thus requiring only a fraction of the systemic dose. Liquid injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal, and intramuscular injection, drip infusions, etc. These injectable preparations can be prepared using publicly known methods. For example, injectable preparations can be prepared by dissolving, suspending, or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. Examples of aqueous injection media include physiological saline solution, an isotonic solution containing glucose and other excipients, etc., which can be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80, HCO-50 (hydrogenated castor oil polyoxyethylene adduct)), etc.For the oily medium, sesame oil, soybean oil, etc., are used, which can be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled into a suitable ampoule. A pharmaceutical composition of the present invention can be administered subcutaneously or intravenously using a standard needle and syringe. Furthermore, with regard to subcutaneous administration, a pen delivery device is readily applicable for administering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device typically uses a replaceable cartridge containing the pharmaceutical composition. Once the entire pharmaceutical composition in the cartridge has been administered and the cartridge is empty, this empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge.Instead, the disposable pen delivery device comes pre-filled with the pharmaceutical composition, held in a reservoir within the device. Once the reservoir is emptied, the entire device is discarded. Numerous auto-injector and reusable pen delivery devices have applications in the subcutaneous administration of a pharmaceutical composition of the present invention. Examples include, but are certainly not limited to, AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX 75 / 25™ pen, HUMALOG™ pen, HUMALIN 70 / 30™ pen (Eli Lilly and Co, Indianapolis, IN), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™ and OPTICLIK™ (sanofi-aventis, Frankfurt, Germany), to name just a few.Examples of disposable pen delivery devices that have applications in the subcutaneous administration of a pharmaceutical composition of the present invention include, but are certainly not limited to, the SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and crczLn / Lznz / E / Yii the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousands Oaks, CA), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, LP), and the HUMIRA™ pen (Abbott Labs, Abbott Park, IL), to name only a few. Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared in unit-dose dosage forms suitable for adjusting the dose of the active ingredients. Such unit-dose dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the aforementioned antibody contained is generally approximately 5 to approximately 500 mg per unit-dose dosage form; particularly in the injection form, it is preferred that the aforementioned antibody be contained in approximately 5 to approximately 100 mg, and in approximately 10 to approximately 250 mg for the other dosage forms. Management regimes According to certain embodiments of the present invention, multiple doses of an anti-RET antibody can be administered to a subject over a defined period of time. Methods according to this aspect of the invention comprise sequentially administering multiple doses of an anti-RET antibody to a subject. As used herein, sequential administration means that each dose of the anti-RET antibody is administered to the subject at a different time, for example, on different days separated by a predetermined interval (for example, hours, days, weeks, or months). The present invention includes methods comprising sequentially administering to the patient a single initial dose of an anti-RET antibody, followed by one or more secondary doses of the anti-RET antibody and optionally followed by one or more tertiary doses of the anti-RET antibody. The terms initial dose, secondary dose, and tertiary dose refer to the timing of RET antibody administration. Therefore, the initial dose is the dose given at the start of the treatment regimen (also called the baseline dose); secondary doses are the doses given after the initial dose; and tertiary doses are the doses given after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of RET antibody, but they generally differ in frequency of administration. In certain modalities, however, the amount of RET antibody contained in the initial, secondary, and / or tertiary doses varies (e.g., adjusted up or down as appropriate) during the course of treatment.In certain modalities, two or more (e.g., 2, 3, 4 or 5) doses are administered at the beginning of the treatment regimen as a loading dose followed by subsequent doses that are administered less frequently (e.g., maintenance doses). In an exemplary embodiment of the present invention, each secondary and / or tertiary dose is administered from 1 to 26 (for example, 1, 1V2, 2, 2V2, 3, 31 / 2, 4, 41 / 2, 5, 5V2, 6, 6V2, 7, 71 / 2, 8, 8V2, 9, 91 / 2, 10, 101 / 2, 11, 111 / 2, 12, 121 / 2, 13, 131 / 2, 14, 14V2, 15, 151 / 2, 16, 16V2, 17, 171 / 2, 18, 18V2, 19, 191 / 2, 20, 201 / 2, 21, 211 / 2, 22, 22V2, 23, 231 / 2, 24, 241 / 2, 25, 251 / 2, 26, 26V2, or more) weeks after the immediately preceding dose. The phrase "the immediately preceding dose," as used herein, means, in a multiple-administration sequence, the dose of RET antibody administered to a patient before the administration of the next dose in the sequence without intervening doses. The methods according to this aspect of the invention may comprise administering to a patient any number of secondary and / or tertiary doses of an antibody against RET. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (for example, 2, 3, 4, 5, 6, 7, 8 or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (for example, 2, 3, 4, 5, 6, 7, 8 or more) tertiary doses are administered to the patient. In regimens involving multiple secondary doses, each secondary dose may be administered as frequently as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2 weeks after the immediately preceding dose. Similarly, in regimens involving multiple tertiary doses, each tertiary dose may be administered as frequently as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2 to 4 weeks after the immediately preceding dose. Alternatively, the frequency with which secondary and / or tertiary doses are administered to a patient may vary during the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the individual patient's needs after clinical examination. Therapeutic uses of antibodies Due to their binding to / interaction with the RET protein expressed in certain cells and tissues, the present antibodies are useful for preventing the interaction of the RET protein with one or more ligand / coreceptor complexes, for example, GDNF / GFRa1, artemin / GFRa3, neurturin / GFRa2, or persephin / GFRa4. Given the ability of the anti-RET antibodies of the invention to prevent or inhibit this interaction, the antagonistic antibodies of the present invention may be useful for inhibiting the growth of tumor cells when the tumor cell depends on RET signaling for growth, or they may be useful for inhibiting pain associated with cancer, as well as pain associated with other diseases or disorders in which RET activation or signaling plays a role.The antibodies of the present invention can be used to slow the growth and / or metastasis of tumors in a subject with a RET-expressing tumor, or to treat pain associated with the cancerous condition, when administered alone or in conjunction with another antitumor agent or therapeutic regimen, or with one or more agents used to further improve the pain associated with the condition. Alternatively, the antibodies of the present invention may be useful in improving at least one symptom associated with the cancerous condition. It is envisaged that the antibodies of the invention may be used alone, or in conjunction with a second or third agent, to treat a RET-associated disease or condition, or to alleviate at least one symptom or complication associated with the RET-associated disease or condition. A RET-associated disease or condition is any disease or condition in which RET is known to be expressed in cells or tissues affected by the disease or condition, and which responds favorably to treatment. OGGZI with a small therapeutic molecule known to inhibit RET activation and / or signaling, or that responds favorably to treatment with an anti-RET antibody of the present invention. The second or third agent may be administered simultaneously with the antibodies of the invention, or may be administered separately, before or after the antibodies of the invention. The second or third agent may be an organic small molecule or a biological agent, such as a protein or a polypeptide. The second or third agent may be synthetic or naturally derived.The second or third agent may be an antitumor agent, such as a chemotherapeutic drug or radiotherapy, or a bone marrow restorative agent, or other agents to reduce fever or pain, another different second antibody that binds specifically to RET, an agent (e.g., an antibody) that binds to a RET ligand, e.g., GDNF, neurturin, artemin, or persephin, or that binds to the co-receptor for RET, such as GFRal, GFRRa2, GFRRa3, or GFRRa4, or a siRNA specific for the RET molecule. In another embodiment of the invention, the present antibodies are used to prepare a pharmaceutical composition for treating patients with a RET-associated disease or condition. In another embodiment of the invention, the present antibodies are used to prepare a pharmaceutical composition to reduce tumor cell proliferation or reduce tumor burden in a patient with a tumor that depends on RET signaling for growth. In a further embodiment of the invention, the present antibodies are used as adjunctive therapy with any other agent useful for treating a RET-associated disease or condition, including a chemotherapeutic agent, radiotherapy, a bone marrow regenerator, a second RET antibody or any other antibody specific for a RET antigen, or an antibody specific for GDNF or GFRα, or any other palliative therapy known to the art.The antibodies of the invention are useful for the treatment, prevention, and / or improvement of any disease, disorder, or condition associated with RET activity, or for improving at least one symptom associated with the disease, disorder, or condition, or for relieving pain associated with such disease, disorder, or condition. Exemplary conditions, diseases, and / or disorders, and / or pain associated with such conditions, diseases, or disorders, that may be treated with the anti-RET antibodies of the present invention include acute or chronic pain, including, but not limited to, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, irritable bowel syndrome, inflammatory bowel syndrome, visceral pain including abdominal pain, osteoarthritis pain, gout, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, and back pain.Headache or neck pain, breakthrough pain, post-surgical pain, bone pain, cancer pain. Other conditions treatable with the antibodies and therapeutic methods of the invention included thyroid cancers, familial medullary thyroid carcinoma (FMTC) syndrome, sporadic medullary carcinoma (MTC), multiple endocrine neoplasia syndromes MEN2A and MEN2B, prostate cancer, breast cancer, cervical cancer, colon cancer, or bladder cancer, and the pain associated with these conditions. Cancers treatable by the antibodies of the invention may be solid tumors or blood-borne tumors, such as leukemia. The antibodies of the invention or antigen-binding fragments thereof may also be used to treat the following conditions: acute, chronic, or fracture-related non-malignant bone pain; rheumatoid arthritis,spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; pancreatic pain; chronic headache; tension headache; HIV-associated neuropathy; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; proximal and distal ectopic discharges; radiculopathy; chemotherapy-induced neuropathic pain; radiation therapy-induced neuropathic pain; postmastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom pain; intractable pain; musculoskeletal pain; joint pain; acute gout pain; mechanical low back pain; neck pain; tendinitis; injury / exercise pain; pyelonephritis; appendicitis; cholecystitis; bowel obstruction; hernias; chest pain, including cardiac pain; pelvic painRenal colic pain; acute obstetric pain, including labor pain; cesarean section pain; pain from burns and trauma; endometriosis; shingles pain; sickle cell anemia; acute pancreatitis; orofacial pain, including sinus pain and dental pain; multiple sclerosis pain; leprosy pain; Behcet's disease pain; adiposis dolor; phlebitic pain; Guillain-Barré pain; leg and toe pain; Haglund's syndrome; Fabry disease pain; bladder and urogenital disease; overactive bladder; painful bladder syndrome; interstitial cystitis; or prostatitis. Combination therapies As noted above, the methods of the present invention, according to certain embodiments, comprise administering to the subject one or more additional therapeutic agents in combination with an anti-RET antibody. As used herein, the expression "in combination with" means that the additional therapeutic agents are administered before, after, or at the same time as the pharmaceutical composition comprising the anti-RET antibody. The term "in combination with" also includes the sequential or concomitant administration of the anti-RET antibody and a second therapeutic agent. For example, when administered prior to the pharmaceutical composition comprising the anti-RET antibody, the additional therapeutic agent can be administered approximately 72 hours, approximately 60 hours, approximately 48 hours, approximately 36 hours, approximately 24 hours, approximately 12 hours, approximately 10 hours, approximately 8 hours, approximately 6 hours, approximately 4 hours, approximately 2 hours, approximately 1 hour, approximately 30 minutes, approximately 15 minutes, or approximately 10 minutes prior to the administration of the pharmaceutical composition comprising the anti-RET antibody.When administered after the pharmaceutical composition comprising the anti-RET antibody, the additional therapeutic agent can be administered approximately 10 minutes, approximately 15 minutes, approximately 30 minutes, approximately 1 hour, approximately 2 hours, approximately 4 hours, approximately 6 hours, approximately 8 hours, approximately 10 hours, approximately 12 hours, approximately 24 hours, approximately 36 hours, approximately 48 hours, approximately 60 hours, or approximately 72 hours after the administration of the crczLn / Lznz / E / Yii pharmaceutical composition comprising the anti-RET antibodies.Concurrent administration or administration with the pharmaceutical composition comprising the anti-RET antibody means that the additional therapeutic agent is administered to the subject in a separate dosage form within 5 minutes (before, after, or at the same time) as the administration of the pharmaceutical composition comprising the anti-RET antibody, or administered to the subject as a single combination dosage formulation comprising both the additional therapeutic agent and the anti-RET antibody. Combination therapies may include an anti-RET antibody of the invention and any additional therapeutic agent that can be advantageously combined with an antibody of the invention, or with a biologically active fragment of an antibody of the invention. For example, a second or third therapeutic agent may be used to help reduce the tumor burden in the patient, such as a chemotherapy agent or radiation therapy that inhibits tumor cell proliferation. Alternatively, antibodies may be used as adjunctive therapy after surgical removal of the tumor and may be used alone or in conjunction with a chemotherapy agent, radiation therapy, or a bone marrow regenerator. Antibodies may also be used in conjunction with other therapies, as described above, including a second RET-specific antibody, an antibody specific for a RET ligand, or an antibody or fusion molecule that binds to GFRal (See SEQ ID NO: 308). Diagnostic uses of antibodies The anti-RET antibodies of the present invention can also be used to detect and / or measure RET in a sample, for example, for diagnostic purposes. It is anticipated that confirmation of a disease or condition believed to be associated with RET can be achieved by measuring the presence of RET in, for example, a biopsy sample from a tumor (i.e., tumor cells) that depends on growth through RET signaling. Exemplary diagnostic assays for RET may comprise, for example, contacting a sample obtained from a patient with an anti-RET antibody of the invention, wherein the anti-RET antibody is labeled with a detectable tag or reporter molecule or is used as a capture ligand to selectively isolate a cell expressing the RET protein from patient samples.Alternatively, an unlabeled anti-RET antibody can be used in diagnostic applications in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, such as 3H, 14C, 32P, 35S, or 125I; a fluorescent or chemiluminescent component such as fluorescein isothiocyanate or rhodamine; or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure RET containing the F protein in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS). Samples that can be used in RET diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a patient that contains detectable amounts of RET protein, or fragments thereof, under normal or pathological conditions. Generally, RET levels in a particular sample obtained from a healthy patient (e.g., a patient not affected by a disease or condition associated with the presence of RET) will be measured to initially establish a baseline, or standard, level of RET protein. This baseline RET level can then be compared against RET levels measured in samples obtained from individuals suspected of having a disease or condition associated with RET, or symptoms associated with such conditions. Examples The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors consider to be their invention. Every effort has been made to ensure accuracy with respect to the numbers used (e.g., quantities, temperatures, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise stated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is atmospheric or near atmospheric pressure. Example 1. Generation of human antibodies against the RET protein An immunogen comprising any of the following may be used to generate antibodies against RET. In certain embodiments, the antibodies of the invention are obtained from mice immunized with a primary immunogen, such as a full-length RET protein (See, for example, SEQ ID NO: 310 for the human isoform RET51, also found in accession number ATCC NP_066124.1; and SEQ ID NO: 312 for the human isoform RET9, also found in accession number ATCC NP_065681.1, both having signal sequences of residue numbers 1-28). Mice may receive one or more booster injections containing the same molecule, or they may be boosted with immunogenic fragments of it, such as with the human RET extracellular domain, ranging from amino acids 1-635 of SEQ ID NO: 313, which is also found in accession number ATCC NP_066124.1 with a signal sequence ranging from amino acid residues 1-28).In certain modalities, mice are injected with the full-length RET protein, followed by boosting with any of the constructs shown as SEQ ID NO: 305, 306, 307 and 313 or with a recombinantly prepared molecule. In certain embodiments, the antibodies of the invention are obtained from mice immunized with a primary immunogen, such as a biologically active RET molecule, an immunogenic fragment of the RET protein, or DNA encoding the full-length protein or the active fragment thereof. The immunogen may be administered to the animal by any route, including, but not limited to, intramuscular, subcutaneous, intravenous, or intranasal. In certain modalities, the full-length RET protein or fragments thereof can be used to prepare monospecific, bispecific, or multispecific antibodies. The full-length protein, or a fragment thereof, used as immunogens as previously described, was administered directly, with an adjuvant to stimulate the ceczLn / Lznz / E / Yu immune response, to a VELOCIMMUNE® mouse containing DNA encoding the kappa light chain and heavy chain variable regions of human immunoglobulin. The antibody immune response was monitored using a RET immunoassay. When the desired immune response was achieved, splenocytes were collected and fused with mouse myeloma cells to preserve their viability and form hybridoma cell lines. The hybridoma cell lines were screened and selected to identify cell lines that produce RET-specific antibodies.Using this technique, and the various immunogens described above, several chimeric antibodies were obtained (i.e., antibodies possessing human variable domains and mouse constant domains); certain exemplary antibodies generated in this way were named, for example, H2M7086N. Anti-RET antibodies were also isolated directly from antigen-positive B cells without fusion with myeloma cells, as described in US patent 2007 / 0280945A1, incorporated herein specifically by reference in its entirety. Using this method, several fully human anti-RET antibodies (i.e., antibodies possessing both human variable and human constant domains) were obtained; The exemplary antibodies generated in this way were designated as follows: H4H8044P, H4H8045P, H4H8046P, H4H8048P, H4H8056P, H4H8058P, H4H8060P, H4H8062P, H4H8066P, H4H8067P, H4H8071P, H4H8076P, H4H8079P, H4H8080P, H4H8083P, H4H8084P, H4H8085P and H4H8087P. The biological properties of the exemplary antibodies generated according to the methods in this Example are described in detail in the Examples below. Example 2 Heavy and light chain variable region amino acid sequences Table 1 presents the heavy and light chain variable region amino acid sequence pairs of selected antibodies specific for the RET protein and their corresponding antibody identifiers. Antibodies are typically named herein according to the following nomenclature: Prefix Fe (e.g., H4H, H1M, H2M), followed by a numerical identifier (e.g., 7086 as shown in Table 1), followed by a suffix P or N. Thus, according to this nomenclature, an antibody might be named, for example, H2M7086N. The prefixes H4H, H1M, and H2M in the antibody designations used herein indicate the particular Fe region of the antibody. For example, an H2M antibody has a mouse IgG2 Fci, while an H4H antibody has a human IgG4 Fe.As an expert in the field will appreciate, an H1M or H2M antibody can be converted into an H4H antibody and vice versa, but in either case, the variable domains (including the CDRs), indicated by the numerical identifiers shown in Table 1, will remain the same. Antibodies that have the same numerical antibody designation but differ by a letter suffix N, B, or P refer to antibodies that have heavy and light chains with identical CDR sequences but with sequence variations in regions outside the CDR sequences (i.e., in the frame regions). Thus, the N, B, and P variants of a particular antibody have identical CDR sequences within their heavy and light chain variable regions but differ from each other within their frame regions. crczLn / Lznz / E / Yii Table 1 Antibody Designation SEQ ID NO: HCVR HCDR1 HCDR2 HCDR3 LCVR LCDR1 LCDR2 LCDR3 H2M7086N 2 4 6 8 10 12 14 16 H4H8044P 18 20 22 24 26 28 30 32 H4H8045P 34 36 38 40 42 44 46 48 H4H8046P 50 52 54 56 58 60 62 64 H4H8048P 66 68 70 72 74 76 78 80 H4H8056P 82 84 86 88 90 92 94 96 H4H8058P 98 100 102 104 106 108 110 112 H4H8060P 114 116 118 120 122 124 126 128 H4H8062P 130 132 134 136 138 140 142 144 H4H8066P 146 148 150 152 154 156 158 160 H4H8067P 162 164 166 168 170 172 174 176 H4H8071P 178 180 182 184 186 188 190 192 H4H8076P 194 196 198 200 202 204 206 208 H4H8079P 210 212 214 216 218 220 222 224 H4H8080P 226 228 230 232 234 236 238 240 H4H8083P 242 244 246 248 250 252 254 256 H4H8084P 258 260 262 264 266 268 270 272 H4H8085P 274 276 278 280 282 284 286 288 H4H8087P 290 292 294 296 298 300 302 304 ΟΓΓΖίη / ίζηζ / Ε / γι Example 3. Surface plasmon resonance-derived binding affinities and kinetic constants of human anti-RET monoclonal antibodies The binding affinities and kinetic constants of human anti-RET antibodies were determined by surface plasmon resonance (Biacore T200) at 25 °C and 37 °C (Tables 2-3). The antibodies, expressed as human IgG4 Fe (i.e., designations Ή4H), were captured on a human anti-Fc sensor surface (mAb capture format), and monomeric (hRET.mmh; SEQ ID NO: 305, macaca fascicularis (mf) RET.mmh; SEQ ID NO: 306) or soluble dimeric (hRET.mFc; SEQ ID NO: 307) RET protein was injected onto the sensor surface. The binding equilibrium dissociation constants (Kd) and dissociative half-lives (ti / 2) were calculated from the kinetic rate constants as: Kd [M] = kd / ka; and ti / 2 (min) = (ln2 / (60*kd). The calculations were performed using the BiacoreT200 v1.0 evaluation software. Several antibodies of the invention showed sub-nanomolar affinities for human and monkey RET protein (Tables 2-3). Table 2: Biacore binding affinities of human mAb Fe at 25 °C Union at 25 °C / Mab Capture Format AbPID Analito ka (Ms1) Kd (s1) KD (Molar) t1 / 2 (min) H4H7086N hRET.mmh TBD TBD TBD TBD hRET.mFc TBD TBD TBD TBD mfRET.mmh TBD TBD TBD TBD H4H8066P hRET.mmh 1.27E+05 2.57E-04 2.02E-09 45 hRET.mFc 2.07E+05 1.20E-04 5.80E-10 96 mfRET.mmh 6.43E+04 8.82E-04 1.37E-08 13 H4H8067P hRET.mmh 1.11 E+05 2.35E-04 2.12E-09 49 hRET.mFc 1.68E+05 1.58E-04 9.40E-10 73 mfRET.mmh 1.08E+05 4.15E-02 3.85E-07 0.3 H4H8071P hRET.mmh 1 56E+05 2.19E-04 1.41 E-09 53 hRET.mFc 2.00E+05 1.79E-04 8.90E-10 65 mfRET.mmh 1.17E+05 2.72E-04 2.32E-09 43 H4H8076P hRET.mmh 2.24E+05 3.38E-04 1.51 E-09 34 hRET.mFc 2.50E+05 1.71 E-04 6.86E-10 68 mfRET.mmh 2.12E+05 3.27E-04 1.54E-09 35 H4H8079P hRET.mmh 1 43E+05 3.84E-04 2.68E-09 30 hRET.mFc 2.09E+05 1.51 E-04 7.20E-10 77 mfRET.mmh 1.17E+05 4.35E-04 3.73E-09 27 H4H8044P hRET.mmh 8.88E+04 4.88E-04 5.49E-09 24 hRET.mFc 1 .07E+05 2.11 E-04 1.97E-09 55 mfRET.mmh 9.20E+04 1.35E-03 1.47E-08 9 H4H8045P hRET.mmh 2.79E+05 2.46E-04 8.83E-10 47 hRET.mFc 3.81 E+05 8.71 E-05 2.29E-10 133 mfRET.mmh 1.92E+05 2.80E-03 1.46E-08 4 H4H8046P hRET.mmh 3.06E+05 3.01 E-04 9.84E-10 38 hRET.mFc 2.80E+05 1.81 E-04 6.45E-10 64 mfRET.mmh 2.78E+05 3.15E-04 1.13E-09 37 H4H8048P hRET.mmh 2.54E+05 4.93E-04 1.94E-09 23 hRET.mFc 2.31 E+05 2.67E-04 1.16E-09 43 mfRET.mmh 2.30E+05 5.35E-04 2.33E-09 22 H4H8080P hRET.mmh 2.11 E+05 5.02E-04 2.38E-09 23 hRET.mFc 1.83E+05 2.42E-04 1.32E-09 48 mfRET.mmh NB NB NB NB H4H8083P hRET.mmh 1.92E+05 4.84E-04 2.52E-09 24 hRET.mFc 1.97E+05 2.24E-04 1.14E-09 52 mfRET.mmh 2.07E+05 7.11 E-04 3.44E-09 16 H4H8084P hRET.mmh 7.23E+05 3.75E-04 5.18E-10 31 hRET.mFc 7.20E+05 2.04E-04 2.84E-10 57 mfRET.mmh 6.95E+05 3.93E-04 5.65E-10 29 H4H8085P hRET.mmh 8.01 E+04 1.87E-04 2.34E-09 62 hRET.mFc 9.40E+04 1.25E-04 1.33E-09 92. cprzLn / Lznz / E / Yi mfRET.mmh 6.60E+04 2.25E-04 3.40E-09 51 H4H8087P hRET.mmh 8.96E+05 2.42E-04 2.70E-10 48 hRET.mFc 1 22E+06 1717-Ε041-ΕE-04. 108 mfRET.mmh 6.41 E+05 2.72E-04 4.24E-10 42 H4H8056P hRET.mmh 2.11 E+05 5.39E-04 2.56E-09 21 hRET.mFc 1.85E+05.024-04. 1.47E-09 42 mfRET.mmh 2.16E+05 5.83E-04 2.69E-09 20 H4H8058P hRET.mmh 2.48E+05 5.18E-04 2.09E-09 22 hRET.mFc 2.09E-35+09 1.10E-09 45 mfRET.mmh 2.30E+05 5.40E-04 2.35E-09 21 H4H8060P hRET.mmh 7.61 E+05 3.11 E-04 4.09E-10 37 hRET.mFRET. 1.79E-10 78 mfRET.mmh 7.51 E+05 3.93E-04 5.23E-10 29 H4H8062P hRET.mmh 5.05E+05 3.70E-04 7.33E-10 31 hRET.mF. 4.90E-10 53 mfRET.mmh 5.01 E+05 7.33E-04 1.46E-09 16 NB: No binding is observed under the conditions used. CPfZ LO / LZnZ / Ε / ΥΙΛΙ Table 3: Biacore binding affinities of human Fe mAbs at 37 °C Union at 37 °C / Mab Capture Format AbPID Analito ka (Ms1) Kd (s1) KD (Molar) t1 / 2 (min) H4H7086N hRET.mmh TBD TBD TBD TBD hRET.mFc TBD TBD TBD TBD mfRET.mmh TBD TBD TBD TBD H4H8066P hRET.mmh 1.95E+05 1.06E-03 5.43E-09 11 hRET.mFc 2.62E+05 3.35E-04 1.28E-09 34 mfRET.mmh 8.19E+04 3.23E-03 3.94E-08 4 H4H8067P hRET.mmh 1.59E+05 1.16E-03 7.31 E-09 10 hRET.mFc 2.04E+05 4.58E-04 2.24E-09 25 mfRET.mmh 3.07E+05 6.03E-02 1.96E-07 0.2 H4H8071 P hRET.mmh 2.36E+05 8.96E-04 3.79E-09 13 hRET.mFc 3.00E+05 3.12E-04 1.04E-09 37 mfRET.mmh 1.61 E+05 1.14E-03 7.04E-09 10 H4H8076P hRET.mmh 3.15E+05 1.36E-03 4.31 E-09 9 hRET.mFc 3.14E+05 6.75E-04 2.15E-09 17 mfRET.mmh 2.89E+05 1.40E-03 4.84E-09 8 H4H8079P hRET.mmh 2.07E+05 1.89E-03 9.10E-09 6 hRET.mFc 2.61 E+05 5.23E-04 2.00E-09 22 mfRET.mmh 1.54E+05 2.05E-03 1.33E-08 6 H4H8044P hRET.mmh 1.51 E+05 2.81 E-03 1.86E-08 4 hRET.mFc 1.37E+05 8.50E-04 6.21 E-09 14 mfRET.mmh 1.08E+05 5.21 E-03 4.85E-08 2 H4H8045P hRET.mmh 3.95E+05 1.27E-03 3.22E-09 9 hRET.mFc 4.59E+05 3.82E-04 8.34E-10 30. mfRET.mmh 2.61 E+05 1.31 E-02 5.03E-08 1 H4H8046P hRET.mmh 7.18E+05 1.30E-03 1.81 E-09 9 hRET.mFc 3.38E+05 6.94E-04 2.05E-09 17 h4H8048P h4H8048P hRET.mmh 7.04E+05 1.35E-03 1.92E-09 9 hRET.mmh 3.39E+05 2.42E-03 7.14E-09 5 mfRET.mmh 2.95E+05 2.54E-03 8.60E-09 5 H4H8080P hRET.mmh 2.85E+05 2.67E-03 9.35E-09 4 hRET.mFc 2.69E+05 1.07E-03 3.98E-09 11 mfRET.mmh NB NB NB NB H4H8083P hRET.mmh 2.82E+05 2.55E-03 9.04E-09 5 hRET.mFc 2.64E+05 8.00E-04 3.02E-09 14 mfRET.mmh 2.83E+05 4.00E-03 1.42E-08 3hRET.mmh 1.06E+06 1.65E-03 1.56E-09 7 H4H8084P hRET.mFc 1.05E+06 8.50E-04 8.09E-10 14 mfRET.mmh 1.01 E+06 1.78E-03 1.76E-09 6 hRET.mmh 1.44E+05 8.97E-04 6.23E-09 13 H4H8085P hRET.mFc 9.90E+04 5.50E-04 5.50E-09 21 mfRET.mmh 1.52E+05 1.26E-03 8.30E-09 9 hRET.mmh 1.27E+06 1.23E-03 9.68E-10 9 H4H8087P hRET.mFc 1.26E+06 4.41 E-04 3.49E-10 26 mfRET.mmh 8.36E+05 1.31 E-03 1.57E-09 9 hRET.mmh 3.26E+05 2.89E-03 8.88E-09 4 H4H8056P hRET.mFc 2.27E+05 1.28E-03 5.62E-09 9 mfRET.mmh 3.03E+05 3.13E-03 1.03E-08 4 hRET.mmh 5.28E+05 2.21 E-03 4.18E-09 5 H4H8058P hRET.mFc 5.52E+05 1.21 E-03 2.18E-09 10 mfRET.mmh 5.43E+05 2.26E-03 4.16E-09 5 hRET.mmh 1.11 E+06 1.57E-03 1.41 E-09 7 H4H8060P hRET.mFc 1.06E+06 5.92E-04 5.58E-10 19 mfRET.mmh 1.12E+06 2.09E-03 1.88E-09 6 hRET.mmh 6.82E+05 1.81 E-03 2.65E-09 6 H4H8062P hRET.mFc 3.66E+05 8.80E-04 2.40E-09 13 mfRET.mmh 6.78E+05 4.28E-03 6.31 E-09 3. NB: No bonding is observed under the conditions used. crrzLn / Lznz / E / Yii Example 4. Anti-RET antibodies potentially block the binding of human RET to the GFRα1 / GDNF cocomplex The ability of anti-RET antibodies to block the binding of human RET to the GDNF:GFRa1 co-complex bound to the pre-complexed plaque was evaluated using a competitive sandwich ELISA. Most RET antibodies potently blocked the binding of RET to the plaque-bound GDNF / GFRa1 co-complex (Table 4). ICso values ranged from 5.2 nM to below the theoretical minimum of the assay (250 pM), with maximum blockade ranging from 72–96%. Detailed methods Recombinant human dimeric GDNF (R&D Systems) and human GFRal .mFc (SEQ ID: 308) were mixed at a 1:1 molar ratio in FBS to obtain a final co-complex concentration of ~2.0 pg / mL. The GDNF-GFRa1 co-complex was incubated for 1 hour at room temperature (TA) before coating 96-well microtiter plates overnight at 4 °C. Non-specific binding sites were blocked with BSA. Separately, 1 nM of biotinylated monomeric RET protein (biot-hRET.mmh; SEQ ID: 305) was titrated with varying amounts of serially diluted antibodies ranging from 0 to 120 nM. The RET-antibody mixtures were incubated for 1 hour at room temperature (RT) and then transferred to microtiter plates pre-coated with the hGDNF / hGFRal co-complex. Binding was allowed to proceed for 1 hour at RT followed by extensive washing. Plate-bound biot-hRET.mmh was detected with HRP-conjugated streptavidin and developed with TMB. Plates were read at 450 nm, and data analysis was performed using a sigmoidal dose-response model within Prism™ software. ICso values, calculated as the antibody concentration required to block 50% of hRET binding to hGDNF / hGFRα, were used as an indicator of blocking potency. Maximum blocking values represent the ability of anti-RET antibodies to block hRET binding relative to the baseline. Baseline values were calculated as the absorbance measured at a constant amount of hRET on the dose curve (0% block) and the absorbance measured without added hRET (100% block). Absorbance values from the wells containing the highest concentration for each antibody were used to determine the percentage of block at the maximum concentration of antibodies tested. Table 4 shows a summary of the ICso values and the maximum percentage of block. Table 4. IC5o values for anti-RET antibodies blocking the pre-complexed GDNF / GFRa1 coated plate ορρζίη / ίζηζ / Ε / γι AbPID Blocking Biot-hRET.mmh 1nM against pre-complexed GDNF / GFRa1 coated plate IC50, [M] % block max H2M7086N 3.3E-10 96 H4H7086N 3.9E-10 97 H4H8044P 5.2E-09 91 H4H8045P 3.4E-10 75 H4H8046P <2.5E-10* 95 H4H8048P <2.5E-10* 96 H4H8056P IC 73 H4H8058P 2.5E-10 93 H4H8060P <2.5E-10* 95 H4H8062P <2.5E-10* 97 H4H8066P 4.1 E-10 57 H4H8067P <2.5E-10* 95 H4H8071P 3.6E-10 72 H4H8076P <2.5E-10* 95 H4H8079P <2.5E-10# 93 H4H8080P <2.5E-10# 82 H4H8083P <2.5E-10# 95 H4H8084P <2.5E-10# 96 H4H8085P <2.5E-10# 96 H4H8087P <2.5E-10# 92 crczLn / Lznz / E / Yii#Below the theoretical minimum of the assay of <2.5E-10 M; CI inconclusive Example 5. Anti-RET antibodies inhibit ligand-dependent RET signaling in an SRE-luciferase reporter assay and show strong internalization In this example, the effect of anti-RET antibodies on RET signaling and internalization was examined using engineered MCF7 and hRET reporter cell lines. The glial ligands GDNF and Artemin trigger RET activation by forming a high-affinity co-complex with GFR1 or GFR3, respectively, bringing together two RET molecules and initiating phosphorylation of specific tyrosine residues. RET transphosphorylation activates several downstream intracellular cascades, and the upregulation of RET signaling has been implicated in various disease pathologies, including cancer (Borrello, MG, et al., (2013), Expert. Opin. Ther. Targets 17(4): 403-419). To test the ability of RET antibodies to block GDNF-mediated signaling, the MCF7 human breast adenocarcinoma cell line, which expresses RET and GFRα, was transduced with a serum response factor (SRE)-regulated luciferase reporter gene to create an MCF7 / SRE-Luc line. The antibodies of this invention showed potent inhibition of GDNF-stimulated RET signaling, with ICsα values ranging from 143 pM to >100 nM (Table 5). The percentage of inhibition ranged from 60–100%. Several non-blocking antibodies were also identified; H4H8085P stimulated luciferase activity to 50% of the levels observed with GDNF, while H4H8044P, H4H8076P, and H4H8046P were weaker activators of the luciferase response (2–5% activation). To determine whether antibodies that blocked GDNF-mediated RET signaling would also be effective against artemin-triggered activity, genetically modified HEK293 / hGFRa3 / hRET SRELuc cell lines were constructed. Most of the GDNF-dependent RET signaling blockers were also blockers of artemin-dependent signaling activity in this cell line (Table 5; column 5–6). Interestingly, H4H8048P was identified as a more potent blocker of artemin-dependent signaling compared to GDNF-dependent signaling, perhaps reflecting different epitopes bound by the GDNF-GFRa1 and artemin-GFRa3 cocomplexes on the RET receptor. Finally, to understand whether the observed blocking activity could also be due to RET receptor degradation following antibody binding, several antibodies were tested in an internalization assay (Table 6). Among the seven antibodies tested, H4H8087P was identified as the strongest internalizer, and H4H8079P and H4H7086P also demonstrated potent internalization. In conclusion, this example illustrates that the anti-RET antibodies of this invention exhibit a range of activating and inhibitory activity on RET signaling in the presence of glial family ligands, GDNF, and artemin. Table 5: IC50 and EC50 values of anti-RET antibodies in the SRE-Luciferase ligand-dependent RET signaling assay crrzLn / Lznz / E / Yii mAb MCF7 / SREluc Prom. IC5D (nM) MCF7 / SREluc Prom % block MCF7 / SRELuc % Activación 293 / hG FRa3 / h RET / SRELuc IC50 (nM) 293 / hGFRa3 / hRET SRE-luc % block H2M7086N 2.6 100 0 4 98 H4H8044P 2.1 85 2 1.6 77 H4H8045P 0.14 69 0 0.42 96 H4H8046P 44 78 5 11.8 91 H4H8048P >100 82 0 8.3 99 H4H8056P 2 73 0 ND ND H4H8058P 5.4 85 0 ND ND H4H8060P >100 87 0 ND ND H4H8062P 5.2 100 0 ND ND H4H8066P 0.39 60 0 1.5 93 H4H8067P 3.8 91 0 4.8 99 H4H8071P 0.45 84 0 ND ND H4H8076P 55.7 74 3 ND ND H4H8079P 0.15 90 0 0.8 96 H4H8080P >100 41 0 341 57 H4H8083P >100 68 0 57 81 H4H8084P 10.4 100 0 2.1 94 H4H8085P NB 0 47 127 72 H4H8087P 0.25 100 0 0.25 100 Table 6: Procedure for internalizing anti-RET antibodies at 37 °C in relation to H4H8087P PID Internalization (%H4H8087P) H4H7086N 59.03 H4H8058P 42.02 H4H8062P 44.94 H4H8067P 58.20 H4H8079P 62.78 H4H8048P 35.37 H4H8087P 100.00 Métodos detallados Generation of stable MCF7 / SRE-Luciferase cell lines MCF7 cells naturally express RET and GFRα. Production of MCF7 / SRELuc cells utilized a stably incorporated SRE-Luciferase generated by MCF7 transduction with the Cignal Lenti SRE Reporter kit (SABiosciences) and a two-week selection in puromycin. The lentivirus expresses the firefly luciferase gene under the control of a minimal CMV promoter and serum response element (SRE) tandem repeats. Generation of stable HEk293 / hGFRal (or 3) / hRET / SRE-Luciferase cell lines Human GFRα (1 or 3) and hRET were stably introduced into HEK293 cells by sequential rounds of Lipofectamine2000-mediated transfection and selected for at least two weeks in 500 pg / mL G418 (hGFRaα or 3) and 100 pg / mL hygromycin B (hRET). Stable double HEK293 cell lines expressing either hGFRa1 / hRET or hGFRa3 / hRET were then transduced using the Cignal Lenti SRE Reporter kit, as previously described, to generate the HEK293 / hGFRa1 / hRET / SRE-Luc cell line and the artemin-responsive HEK293 / GFRa3 / hRET / SRE-Luc cell line. Inhibition of GDNF-stimulated luciferase activity in genetically engineered MCF7 / SRE-Luciferase cell lines Twenty thousand MCF7-SRE-luc cells were seeded in 96-well PDL-coated plates in Optimem + 0.5% FBS and cultured overnight at 37°C, 5% CO2. For inhibition curves, cells were incubated for 1 hour with serially diluted anti-hRET mAbs in the range of 1.6 pM to 1 μM. A constant dose of human GDNF (4–10 pM) was then added, and the cells were incubated for a further 6 hours. To evaluate the activation properties of anti-RET mAbs, MCF7-SRELuc cells were incubated for 6 hours with serially diluted anti-hRET mAbs in the range of 1.6 pM to 1 μM in the absence of ligand. GDNF dose-response curves were measured using serially diluted GDNF, in the range of 0.05 pM to 10 nM, added to antibody-free wells and incubated for 6 hours at 37 °C. Luciferase activity was measured with ONE GLO™ reagent (Promega) and relative light units (RLU) were measured on a Victor luminometer (Perkin Elmer). Inhibition of artemin-stimulated luciferase activity in genetically engineered cell lines HEK293 / hGFRa3 / hRET The inhibition of artemin-stimulated luciferase activity in HEK293 / hGFRa3 / hRET / SRE-Luc cell lines was assessed using anti-RET antibodies via the method described for MCF7 / SRE-Luc cells. To generate inhibition curves, cells were incubated for 1 hour with serially diluted anti-hRET antibodies ranging from 1.6 pM to 1 μM. Cells were then stimulated with a constant dose of hArtemin (100 pM) for 6 hours. Artemin dose-response curves were generated by adding serially diluted hArtemin (0.17 pM–10 μM) to cells for 6 hours at 37 °C without antibody addition. Luciferase activity measurements and curve fitting were performed as described for GDNF-stimulated luciferase activity. Calculation of EC50 / IC50 values EC50 / IC50 values were determined from a four-parameter logistic equation on a 12-point response curve using GraphPad Prism. The percentage of blockade for the highest antibody dose is reported, and data are presented as mean ± standard deviation (SD). crczLn / Lznz / E / Yii Quantitative analysis of the internalization properties of anti-RET antibodies To test the internalization of anti-hRET mAbs, HEK293 / hGFRa1 / hRET / SRE-Luc cells were incubated with antibodies (10 pg / mL) for 30 minutes on ice, followed by a wash. The cells were then incubated with alexa488-conjugated anti-hFc Fab secondary antibodies for 30 minutes, followed by a second wash. The antibodies were allowed to internalize for 4 hours at 37°C or kept at 4°C to prevent internalization. The cells were fixed in 4% formaldehyde, and alexa488 on the cell surface was inactivated by incubation with an anti-alexa488 inactivating antibody for 1 hour at 4°C. The nuclei were stained with Hoechst stain, and images were acquired using the ImageXpress micro XL (Molecular Devices). The total intensity of alexa488 in intracellular vesicles at 37 °C in inactivated samples was quantified using Columbus image analysis software (Perkin Elmer). The total intensity of internalized mAb is expressed as a percentage of the strongest internalized mAb. Example 6. Generation of a bispecific antibody Several bispecific antibodies are generated for use in the practice of the methods of the invention. For example, RET-specific antibodies are generated in a bispecific format (a bispecific) in which variable regions that bind to different domains of the RET protein are joined together to confer dual-domain specificity within a single binding molecule. Properly designed bispecifics can improve the overall efficacy of RET neutralization by increasing both specificity and binding avidity. The variable regions with specificity for individual domains are paired into a structural scaffold that allows each region to bind simultaneously to separate epitopes, or to different regions within a domain.In an example of a bispecific, the heavy-chain variable regions (Vh) of a ligand specific for one domain are recombined with light-chain variable regions (Vl) of a series of ligands specific for a second domain to identify dissimilar Vl pairs that can mate with an original Vh without altering the original specificity for that Vh. In this way, a single Vl segment (e.g., Vl1) can be combined with two different Vh domains (e.g., Vh1 and Vh2) to generate a bispecific composed of two joining arms (Vh1-Vl1 and Vh2-Vl1). The use of a single Vl segment reduces the complexity of the system and thus simplifies and increases the efficiency of the cloning, expression, and purification processes used to generate the bispecific (See, for example, USSN13 / 022759 and US2010 / 0331527). Alternatively, antibodies that bind to RET and a second target, such as, but not limited to, a tumor antigen, can be prepared in a bispecific format using techniques described herein or other techniques known to those skilled in the art. Variable regions of antibodies that bind to distinct regions can be combined with variable regions that bind to relevant sites on, for example, a different antigen to confer dual-antigen specificity within a single binding molecule. Properly designed bispecifics of this nature serve a dual purpose. For example, in the case of a bispecific antibody that binds, i.e., RET and one of its ligands, tumor cell growth could be more effectively inhibited without the need to administer a composition containing two separate antibodies.The cprzLn / Lznz / E / Yii variable regions with RET specificity are combined with a variable region with specificity for one of their ligands and are paired into a structural scaffold that allows each variable region to bind to separate antigens. Bispecific linkers are tested for binding to and functional blocking of the target antigen, e.g., RET, in any of the antibody assays described above. For example, standard methods for measuring binding to soluble proteins are used to assess bispecific interaction, such as Biacore, ELISA, size exclusion chromatography, multi-angle laser scattering, direct scanning calorimetry, and other methods. The binding of bispecific antibodies to both RET and one of its ligands is determined using an ELISA binding assay in which the wells of microtiter plates are coated with synthetic peptides representing the different antigens, and the binding of a bispecific antibody is determined using a secondary detection antibody.Binding experiments can also be performed using surface plasmon resonance experiments, in which the real-time binding interaction of the peptide to the antibody is measured by flowing a peptide or bispecific antibody across a sensor surface that captures the bispecific antibody or peptide, respectively. The in vitro functional blockade of both RET and one of its ligands by a bispecific antibody is determined using any bioassay such as those described herein, or by in vivo protection studies in appropriate animal models, such as tumor-bearing animal models.
Claims
1. An isolated human monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the RE-assembled-during-Transfection (RET) tyrosine kinase receptor, wherein the antibody has one or more of the following characteristics: (a) it is a fully human antibody; (b) it has a Kd ranging from approximately 1.0 x 10⁷ M to approximately 1.0 x 10¹² M as measured by surface plasmon resonance; (c) it inhibits or blocks the binding or interaction of RET with one or more ligands of the GDNF family (GDNF, neurturin, artemin, and persephin) complexed with their corresponding coreceptors (GFRα, GFRβ, GFRγ, and GFRδ, respectively); (d) it inhibits RET signaling mediated by one or more ligands of the GDNF family selected from GDNF, neurturin, artemin, and persephin; (e) enhances internalization / degradation by RET after antibody binding to RET receptor;(f) comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290; or (g) comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298.
2. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody blocks the binding of human RET to the GDNF:GFRa1 co-complex with an ICso value ranging from approximately 100 pM to approximately 7.0 nM.
3. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 2, wherein the antibody blocks the binding of human RET to the GDNF:GFRa1 co-complex with an ICso value ranging from approximately 250 pM to approximately 5.2 nM.
4. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 3, wherein the percentage of human RET blockade of the GDNF:GFRa1 co-complex ranges from approximately 40% to 100%.
5. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 4, wherein the percentage of human RET blockade of the GDNF:GFRa1 co-complex ranges from approximately 57% to approximately 97%.
6. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein GDNF-mediated RET signaling is inhibited with an ICso value ranging from approximately 50 pM to more than 100 nM.
7. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 6, wherein GDNF-mediated RET signaling is inhibited with an ICso value ranging from approximately 143 pM to over 100 nM.
8. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 6, wherein GDNF-mediated RET signaling is inhibited between approximately 40% and approximately 100%.
9. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 7, wherein GDNF-mediated RET signaling is inhibited by approximately 60% to approximately 100%.
10. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein artemin-mediated RET signaling is inhibited with an ICso value ranging from approximately 100 pM to approximately 500 nM.
11. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 10, wherein artemin-mediated RET signaling is inhibited with an ICso value ranging from approximately 250 pM to approximately 341 nM.
12. The isolated human monoclonal antibody or antigen-binding fragment thereof according to claim 11, wherein artemin-mediated RET signaling is inhibited from approximately 57% to approximately 100%.
13. The human monoclonal antibody isolate or antigen-binding fragment thereof according to claim 1, comprising a pair of HCVR / LCVR amino acid sequences selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282 and 290 / 298.
14. An isolated human monoclonal antibody or an antigen-binding fragment thereof that binds specifically to RET, wherein the antibody comprises an HCVR comprising the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within an HCVR amino acid sequence selected from the group consisting of SEQ. ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274 and 290; and an LCVR comprising the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within an LCVR amino acid sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282 and 298.
15. The human monoclonal antibody isolate or antigen-binding fragment according to claim 14, comprising: (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276 and 292; (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278 and 294; ΟΓΓΖίη / ίζηζ / Ε / γι (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280 and 296; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284 and 300;(e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286 and 302; and (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288 and 304.
16. An isolated antibody or antigen-binding fragment thereof that competes for specific binding to RET with an antibody or antigen-binding fragment comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282 and 290 / 298.
17. An isolated antibody or antigen-binding fragment thereof that binds to the same epitope in RET that is recognized by an antibody comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 218, 226 / 234, 242 / 250, 258 / 266, 274 / 282 and 290 / 298.
18. An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment according to any of claims 1 to 17.
19. An expression vector comprising the nucleic acid molecule according to claim 18.
20. A pharmaceutical composition comprising one or more of the antibodies specifically binding to RET, or an antigen-binding fragment thereof according to any of claims 1 to 17 and a pharmaceutically acceptable vehicle or diluent.
21. A method for treating a disorder or condition associated with the expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, or pain associated with the disorder or condition, the method comprising administering one or more antibodies or antigen-binding fragments thereof according to any one of claims 1 to 17, or a pharmaceutical composition comprising one or more antibodies according to any one of claims 1 to 17 to a patient in need thereof.
22. The method according to claim 21, wherein the disorder or condition associated with the expression, activation, or signaling of the RET tyrosine kinase receptor gene, or a rearranged form thereof, is a cancer, and wherein the cancer is selected from the group consisting of thyroid cancer, lung cancer, pancreatic cancer, skin cancer, breast cancer, and a blood-borne cancer crczLn / Lznz / E / Yii.
23. The method according to claim 21, wherein the disorder or condition associated with the expression, activation, or signaling of the RET tyrosine kinase receptor gene, or a rearranged form thereof, is selected from the group consisting of acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, osteoarthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgias, neurodegenerative disorders, neuroendocrine disorders, visceral pain, acute gout, post-herpetic neuralgia, diabetic neuropathy, sciatica, back pain, headache or neck pain, severe or intractable pain, breakthrough pain, post-surgical pain, dental pain, rhinitis, cancer pain, or bladder disorders.
24. A method for inhibiting tumor growth or tumor cell proliferation, wherein the tumor or tumor cell expresses RET, or a rearranged form thereof, the method comprising administering one or more antibodies or antigen-binding fragments thereof according to any one of claims 1 to 17, or a pharmaceutical composition comprising one or more antibodies according to any one of claims 1 to 17 to a patient in need.
25. The method according to claim 24, wherein the tumor is a solid tumor or a blood-borne tumor.
26. The method according to claim 25, wherein the solid tumor is selected from the group consisting of a thyroid tumor, a lung tumor, a pancreatic tumor, a skin tumor, and a breast tumor.
27. The method according to claim 26, wherein the thyroid tumor is a papillary thyroid carcinoma (PTC) or a medullary thyroid carcinoma (MTC).
28. The method according to claim 27, wherein medullary thyroid carcinoma is a hereditary MTC selected from the group consisting of multiple endocrine neoplasia type 2 or 3 (MEN2A, MEN2B) and familial medullary thyroid carcinoma syndrome (FMTC), or wherein medullary thyroid carcinoma is a sporadic MTC.
29. The method according to claim 26, wherein the lung tumor is a pulmonary adenocarcinoma.
30. The method according to claim 26, wherein the lung tumor is a non-small cell lung cancer (NSCLC).
31. The method according to claim 26, wherein the skin tumor is a melanoma.
32. The method according to claim 25, wherein the blood-borne tumor is a leukemia.
33. The method according to claim 32, wherein the cancer is chronic lymphocytic leukemia.
34. A method for downregulating RET expression and / or function, the method comprising administering one or more antibodies or antigen-binding fragments thereof according to any one of claims 1 to 17, or a pharmaceutical composition comprising one or more antibodies according to any one of claims 1 to 17, to a patient in need. CPCZ Ln / Lznz / E / YILI 35. The method according to claim 34, wherein down-modulation of the RET expression and / or function results in down-regulation of a downstream signaling pathway selected from the group consisting of the RAS / RAF pathway and the PI3K pathway.
36. The method according to any of claims 21 to 35, wherein the antibody or antigen-binding fragment is administered to the patient in combination with a second therapeutic agent.
37. The method according to claim 36, wherein the second therapeutic agent is selected from the group consisting of a small molecule tyrosine kinase inhibitor, an antitumor agent, a RET-specific siRNA, a second RET-specific antibody, and a pain-reducing agent.
38. The method according to claim 37, wherein the small molecule tyrosine kinase inhibitor is selected from the group consisting of vandetanib, cediranib, (AZD2171), gefitinib, erlotinib, SU14813, vatalanib, sorafenib, sorafenib (BAY43-9006), sunitinib, cabozantinib, motesanib, XL647, XL-999, AG-013736, BIBF1120, TSU68, GW786034, AEE788, CP-547632, KRN951, CHIR258, CEP7055, OSI-930, ABT-869, E7080, ZK-304709, BAY57-9352, L- 21649, BMS582664, XL-880, XL-184, XL820, RPI-1, PP-1 and NVP-AST478.
39. The method according to claim 37, wherein the antitumor agent is selected from the group consisting of a chemotherapeutic agent, a radionuclide, and an antibody-drug conjugate.
40. The method according to claim 37, wherein the pain-reducing agent is selected from the group consisting of nerve growth factor (NGF) inhibitor (e.g., a small-molecule NGF antagonist or an anti-NGF antibody), aspirin or another NSAID, morphine, steroids (e.g., prednisone), an anti-Nav1.7 antibody or a small-molecule inhibitor of Nav1.7, a Nav1.8 antagonist (e.g., an anti-Nav1.8 antibody or a small-molecule inhibitor of Nav1.8), and a Nav1.9 antagonist (e.g., an anti-Nav1.9 antibody or a small-molecule inhibitor of Nav1.9).9), a cytokine inhibitor (for example, an interleukin-1 (IL-1) inhibitor (such as rilonacept (IL-1 trap); Regeneran) or anakinra (KINERET®, Amgen), a small-molecule IL-1 antagonist or an anti-IL-1 antibody); an IL-18 inhibitor (such as a small-molecule IL-18 antagonist or an anti-IL-18 antibody); an IL-6 or IL-6R inhibitor (such as a small-molecule IL-6 antagonist, an anti-IL-6 antibody or an anti-IL-6 receptor antibody), caspase-1, p38, IKK1 / 2, CTLA4γ inhibitors or an opioid.
